# Human Cytomegalovirus Major Immediate-Early 1 Protein Targets Host Chromosomes by Docking to the Acidic Pocket on the Nucleosome Surface 

Running title: hCMV IE1 Protein Targets the Nucleosome Surface

Katrin Mücke, ${ }^{\text {a }}$ Christina Paulus, ${ }^{\text {a }}$ Katharina Bernhardt, ${ }^{\text {a,* }}$ Katrin Gerrer, ${ }^{\text {a** }}$ Kathrin Schön, ${ }^{a}$ Alina Fink, ${ }^{\text {a }}$ Eva-Maria Sauer, ${ }^{\text {a* }}$ Alexandra Asbach-Nitzsche, ${ }^{\text {a }}$ Thomas Harwardt, ${ }^{\text {a }}$ Bärbel Kieninger, ${ }^{\text {b }}$ Werner Kremer, ${ }^{\text {b }}{ }^{\text {H }}$ Hans Robert Kalbitzer, ${ }^{\text {b }}$ Michael Nevels ${ }^{\text {a } \# ~}$

Institute for Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany ${ }^{\text {a }}$; Institute of Biophysics and Physical Biochemistry, University of Regensburg, Regensburg, Germany ${ }^{\text {b }}$
\#Address correspondence to Michael Nevels, michael.nevels@ukr.de.
*Present address: Katharina Bernhardt, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusettes, USA; Katrin Gerrer, Faculty of Biology, University of Freiburg, Freiburg, Germany; Eva-Maria Sauer, Department of Neurology, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany.
K.M. and C.P. contributed equally to this work.

Word count: 250 (abstract), 9,524 (text excl. abstract, references, and legends)


#### Abstract

The 72-kDa immediate-early 1 (IE1) protein encoded by human cytomegalovirus (hCMV) is a nuclear-localized promiscuous regulator of viral and cellular transcription. IE1 has long been known to associate with host mitotic chromatin, yet the mechanisms underlying this interaction have not been specified. In this study, we identify the cellular chromosome receptor for IE1. We demonstrate that the viral protein targets human nucleosomes by directly binding to core histones in a nucleic acid-independent manner. IE1 exhibits two separable histone interacting regions with differential binding specificities for H2A-H2B and H3-H4. The H2A-H2B binding region was mapped to an evolutionary conserved ten-amino-acid motif within the chromatin tethering domain (CTD) of IE1. Results from experimental approaches combined with molecular modeling indicate that the IE1 CTD adopts a $\beta$-hairpin structure docking with the acidic pocket formed by $\mathrm{H} 2 \mathrm{~A}-\mathrm{H} 2 \mathrm{~B}$ on the nucleosome surface. IE1 binds to the acidic pocket in a way similar to the latency-associated nuclear antigen (LANA) of the Kaposi's sarcoma-associated herpesvirus. Consequently, the IE1 and LANA CTDs compete for binding to nucleosome cores and chromatin. Our work elucidates in detail how a key viral regulator is anchored to human chromosomes and identifies the nucleosomal acidic pocket as a joint target of proteins from distantly related viruses. Based on the striking similarities between the IE1 and LANA CTDs and the fact that nucleosome targeting by IE1 is dispensable for productive replication even in "clinical" strains of hCMV, we speculate that the two viral proteins may serve analogous functions during latency of their respective viruses.


## Introduction

Nuclear DNA is largely organized and controlled through nucleosomes. Each nucleosome typically assembles $146-147$ base pairs (bp) of DNA in 1.65 superhelical turns around a core histone octamer composed of a central H3-H4 tetramer flanked by two H2A-H2B dimers (1, 2). Additionally, linker histone H 1 binds to the nucleosome at the DNA entry-exit points outside the octamer. Thousands of nucleosomes along the DNA compose a "beads-on-a-string" array, which can further condense into higher order chromatin attaining its most compact state during mitosis (reviewed in 3, 4).

Herpesviruses transcribe, synthesize and package their double-stranded DNA genomes in the host cell nucleus where they contend with and exploit chromatin to aid viral replication and persistence. There are several examples of herpesvirus proteins interacting with cellular mitotic and/or interphase chromatin. The viral proteins attach to chromatin through at least three types of non-mutually exclusive molecular targets: DNA, histones, or chromatin-associated non-histone proteins. For instance, Epstein-Barr virus (EBV), a $\gamma$-herpesvirus, encodes the EBV nuclear antigen 1 (EBNA1) which targets host chromatin by interacting with adenosine/thymidine-rich DNA sequences (5) and EBNA1 binding protein 2 (6-9). In contrast, the latency-associated nuclear antigen 1 (LANA1 or LANA) encoded by another $\gamma$-herpesvirus, Kaposi’s sarcomaassociated herpesvirus (KSHV), associates with chromatin through complex formation with nonhistone factors including methyl CpG-binding protein (10) as well as with core histones H2AH2B (11, 12) and, potentially, linker histone H1 (13). In fact, the crystal structure of a nucleosome complexed with the first 23 LANA amino acids revealed that the viral peptide forms a $\beta$-hairpin that specifically interacts with an "acidic pocket" formed by the folded regions of the

H2A-H2B dimer (12). Through chromatin interaction, LANA and other viral proteins assume fundamental roles in the infectious cycles of their respective viruses (see Discussion).

The $72-\mathrm{kDa}$ immediate-early (IE) 1 protein (IE1-72kDa, IE72, or IE1) is a nuclear regulatory phosphoprotein of human cytomegalovirus (hCMV), the prototypic $\beta$-herpesvirus. IE1 is expressed from the hCMV genome at the onset of infection. Together with the $86-\mathrm{kDa}$ IE2 protein (IE2-86kDa, IE86, or IE2), IE1 is the most prominent member of the major IE (MIE) family of hCMV gene products which have been assigned critical functions in virus-host interaction including innate immune modulation and transcriptional regulation (reviewed in 1416). IE1 is required for viral early gene expression and replication in human fibroblasts, at least under conditions of low input multiplicity (17-19). Association of IE1 with condensed chromatin during mitosis was initially described more than 20 years ago (20) and has henceforward been conspicuous to many researchers (e.g., 21-28). The interaction with mitotic chromatin can be observed both during hCMV infection and upon ectopic expression of IE1. Chromosome association was first roughly mapped to MIE exon 4 sequences (20) and, subsequently, to residues 421 to 486 of the 491 -amino-acid viral protein (24). Eventually, the 16 carboxy-terminal residues (amino acids 476 to 491 ) of IE1 were determined to be required and sufficient for mitotic chromatin interaction in transfected cells and were consequently termed the "chromatin tethering domain" (CTD) (22). The ability for chromosome attachment appears to be evolutionary conserved between IE1 orthologs of primate CMVs (21, 22, 29). However, despite being a conserved and distinctive feature of IE1, the mechanisms underlying chromosome association by the viral protein have not been determined.

The present study was designed to identify and precisely delineate the molecular interactions anchoring the hCMV IE1 protein to human chromosomes, and to determine their impact on viral replication in "clinical" strains of hCMV.

## MATERIALS AND METHODS

Plasmids and mutagenesis. For expression in human cells, plasmid constructs derived from pcDNA3 (Life Technologies), pCGN (30), pCMV.TetO (a gift from Roger Everett, University of Glasgow, Scotland), pEGFP-C1 (Clontech), and pME18S (31) were used. For expression in E. coli, plasmid constructs derived from pGEX-KG (32) were used.

Plasmid pcDNA-HA-IE1 encodes the hCMV (Towne) 72-kDa IE1 (pUL123) protein tagged with an Influenza virus hemagglutinin (HA) epitope (21). Plasmid pcDNA-HA-mIE1 encodes an HA-tagged form of the mCMV IE1 (mIE1, pp89) protein and was constructed by inserting a BamH1-EcoRI fragment from pGEX-mIE1 (21) into the same sites of pcDNA-HA-N (33) (a gift from Ronald Hay, University of Dundee, Scotland). For construction of pcDNA-HAIE2, encoding an HA-tagged form of the hCMV 86-kDa IE2 (pUL122) protein, a BglII-EcoRI fragment from pEGFP-IE2 (21) was inserted into the BamHI and EcoRI sites of pcDNA-HA-N. Plasmid pCGN-pp71 encodes an HA-tagged form of the hCMV pp71 (pUL82) protein (34). Plasmid pCMV.TetO.IE1 has been described (40). For pCMV.TetO.IE1M483A, pCMV.TetO.IE1NBM, and pCMV.TetO.IE $1_{1-475}$, mutant hCMV IE1 (Towne) coding sequences were PCR-amplified from template pEGFP-TNIE1 (21) with primers 483 and 1085, 483 and 1086, or 483 and 695, respectively, and inserted into the HindIII and EcoRI sites of pCMVTetO. To generate pEGFP-IE1 ${ }_{476-491}$ and related constructs encoding the enhanced green fluorescent protein (EGFP) fused to the IE1 CTD or to CTD variants with single amino acid substitutions (G476A, G477A, K478A, S479A, T480A, M481A, P482A, M483A, V484A, T485A, R486A, S487A, K488A, A489G, D490A, and Q491A), suitable oligonucleotides (635636 and 703-734) were annealed and inserted into the $\mathrm{Bg} / \mathrm{II}$ and EcoRI sites of pEGFP-C1. A
construct replacing the first two IE1 coding triplets in pEGFP-IE1 $1_{476-491}$ with stop codons (pEGFP-Stop) was generated in the same way using oligonucleotides 737 and 738 . Likewise, pEGFP-LANA ${ }_{5-22}$ was generated by ligating annealed oligonucleotides 639 and 640 via $\operatorname{BglII}$ and EcoRI sites with pEGFP-C1. All constructs expressing human histone H2A (H2A.2, type 1-B/E) were based on pME-Flag-H2A (35) (a gift from Robert Eisenman, Fred Hutchinson Cancer Research Center, Seattle, USA). To generate constructs encoding Flag-tagged H2A with single (E41A, E56A, E61A, E64A, D72A, D90A, E91A, E92A, and E121A) and triple (E61A/E64A/D90A and D90A/E91A/E92A) amino acid substitutions, QuikChange site-directed mutagenesis (Stratagene) was performed according to the manufacturer's instructions using suitable oligonucleotides (787-808).

In pGEX-KG, the BamHI and EcoRI sites served for all cloning reactions. Plasmid pGEX-IE1 encodes the hCMV (Towne) 72-kDa IE1 protein fused to GST (21). To generate pGEX-IE1 $1_{1-475}$, a PCR product amplified from template pGEX-IE1 with primers 637 and 638 was digested with BamHI and EcoRI and ligated with pGEX-KG. For construction of pGEX-IE1 ${ }_{476}$ 491 and related constructs encoding GST fused to the IE1 CTD or to CTD variants with single amino acid substitutions, suitable oligonucleotides (635-636 and 703-734) were annealed and ligated with pGEX-KG. A construct replacing the first two IE1 coding triplets in pGEX-IE1 ${ }_{476-491}$ with two stop codons (pGEX-Stop) was generated in the same way using oligonucleotides 737 and 738. Likewise, pGEX-LANA ${ }_{5-22}$ was generated by ligating annealed oligonucleotides 639 and 640 with pGEX-KG. To construct pGEX-PreS-IE1, a DNA fragment encoding the recognition motif for PreScission Protease (LEVLFQGP) between the GST and IE1 sequences was generated by overlap extension PCR (36) from templates pGEX-KG and pGEX-IE1 with primers 484 and 603-605. The PCR product was digested with BamHI and EcoRI and ligated with pGEX-IE1. Plasmid pGEX-PreS-IE1 was used as a template for PCR with primers 695 and

838 resulting in a DNA fragment that was digested with BamHI and EcoRI and ligated with pGEX-PreS-IE1 to produce pGEX-PreS-IE1 $1_{1-475 .}$. Finally, pGEX-PreS-IE1476-491, pGEX-PreSLANA $_{5-22}$, and pGEX-PreS were generated by ligating annealed oligonucleotides 834 and 835, 836 and 837, or 658 and 659, respectively, with pGEX-PreS-IE1.

As a standard for absolute quantification of hCMV genome copies by real-time quantitative PCR (qPCR), plasmid pCR-RPPH1-UL54P was constructed by a two-step procedure. First, a PCR product comprising 71 bp of hCMV UL54 promoter (UL54P) sequence was amplified from an infected cell genomic DNA template with primers 294 and 295, and was ligated with pCR4TOPO (Life Technologies). Secondly, the resulting construct (pCR-UL54P) was cleaved with PmeI and ligated with a PCR product comprising 83 bp of human ribonuclease P RNA component H1 (RPPH1) sequence amplified from an infected cell genomic DNA template with primers 759 and 765. All oligonucleotide sequences are listed in Table S1.

Cells, viruses, and infections. Human fetal diploid lung fibroblasts (MRC-5) (37) were obtained from the European Collection of Cell Cultures, and early-passage cells (15 to 25 population doublings before senescence) were used in all experiments. MRC-5-derived TetR cells and TetR-IE1 cells expressing inducible wild-type IE1 have been described (40). TetR-IE1 $1_{1-}$ 475 cells expressing inducible CTD-deleted IE1 were generated via lentiviral transduction analogous as described for TetR-IE1 cells (40). The H1299 human lung carcinoma cell line (38) was obtained from the American Type Culture Collection. MRC-5 and H1299 cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) (Life Technologies) supplemented with 10\% fetal calf serum (Life Technologies), $100 \mathrm{U} / \mathrm{ml}$ penicillin, and $100 \mu \mathrm{~g} / \mathrm{ml}$ streptomycin. For TetR, TetR-IE1, and TetR-IE1 $1_{1-475}$ cells, the same medium was further supplemented with $1 \mu \mathrm{~g} / \mathrm{ml}$ puromycin and $300 \mu \mathrm{~g} / \mathrm{ml} \mathrm{G418}$, and induction of IE1 or IE1 $1_{1-475}$ expression was accomplished
by adding doxycycline ( $1 \mu \mathrm{~g} / \mathrm{ml}$ ) 72 h prior to collection. All cells were maintained under humidified conditions at $37^{\circ} \mathrm{C}$ and $5 \% \mathrm{CO}_{2}$. Cultures were regularly screened for mycoplasma contamination.

The wild-type (TNwt) and IE1-deficient (TNdIIE1) viruses of the high passage hCMV Towne strain (39) were described previously (21, 40, 41). The wild-type (TBwt) virus of the low passage hCMV TB40E strain (42) was derived from TB40-BAC4 (43) (a gift from Christian Sinzger, Ulm University, Germany). For the construction of TB40E-based IE1 CTD-deficient bacterial artificial chromosomes (BACs) (pTBIE1 $\left.1_{1-475}\right)$ by en passant mutagenesis, E. coli strain GS1783 (44) carrying TB40-BAC4 was transformed with a DpnI-digested and column-purified PCR product generated using plasmid pLAY2 (45) (a gift from Karsten Tischer, Freie University Berlin, Germany) as a template and oligonucleotides 870 and 871 as primers. "Scarless" removal of CTD-specific sequences by homologous recombination was accomplished following published protocols (44). To control for inadvertent genetic changes, the en passant strategy was also employed to construct "revertant" BACs (pTBrvIE1 $1_{1-475}$ ). To this end, a PCR product comprising MIE exon 4 was generated using TB40-BAC4 as a template and oligonucleotides 876 and 877 as primers. This PCR product was inserted into pUC18 via HindIII and EcoRI sites resulting in plasmid pUC-MIE. In addition, a PCR product comprising a kanamycin resistance (kan) cassette and an SceI cleavage site was generated, using pLAY2 as a template and oligonucleotides 878 and 879 as primers. Following cleavage with $N c o I$, this PCR product was inserted into the NcoI site of pUC-MIE resulting in plasmid pUC-MIE-kan_SceI. Then, GS1783 bacteria carrying BAC pTBIE1 $1_{1-475}$ were transformed with a DpnI-digested and column-purified PCR product generated using plasmid pUC-MIE-kan_SceI as a template and oligonucleotides 880 and 881 as primers, and this was followed by homologous recombination (44). The identity and integrity of pTBIE1 $1_{1-}$

475 and $\mathrm{pTBrvIE} 1_{1-475}$ were verified in comparison to TB40-BAC4 by restriction fragment length and DNA sequencing analyses (data not shown).

Allelic exchange to generate IE1 CTD-deficient ( $\mathrm{pFXIE}_{1-475}$ ) and revertant ( pFXrvIE ) BACs of the low passage hCMV FIX strain $(46,47)$ utilized the following derivatives of transfer plasmid pGS284 (48) (amplified in E. coli strain S17 1 pir): pGS284-FXIE1kanlacZ, pGS284FXMIE, and pGS284-FXIE1 1-475. Plasmid pGS284-FXIE1kanlacZ contains the kan and lacZ genes cloned between sequences flanking the IE1-specific exon four of the hCMV FIX MIE transcription unit. The $\sim 1,000-\mathrm{bp}$ flanking sequences were obtained by PCR amplification using primers 136 and 138 (downstream flanking sequence) or 139 and 140 (upstream flanking sequence), and an EGFP expressing hCMV FIX BAC (pFXwt) (a gift from Dong Yu, Washington University School of Medicine, USA) as template. The amplified downstream flanking sequence was cloned into pGS284 via BglII and NotI sites. Following addition of adenosine nucleotide overhangs to the PCR product, the upstream flanking sequence was first subcloned into vector pCR4-TOPO (Life Technologies) and subsequently inserted via NotI sites into pGS284 carrying the downstream flanking sequence. The kanlacZ expression cassette was released from plasmid pGEM-kanlacZ (YD-C54) (49) and cloned into the PacI site located between the hCMV flanking sequences in the pGS284 derivative described above. For the construction of pGS248-FXMIE, a $\sim 3,000-\mathrm{bp}$ sequence of the MIE region was amplified by PCR using template pFXwt and primers 155 and 156. After phosphorylation, the PCR product was first inserted into the SmaI site of pUC18 to generate pUC18-FXMIE. Plasmid pUC18-FXMIE served as a template for QuikChange site-directed mutagenesis with oligonucleotides 280 and 281 replacing IE1 codon 475 with a stop codon to generate pUC18-FXIE1 $1_{1-475 .}$. Then, FseI-NotI fragments were excised from pUC18-FXMIE and pUC18-FXIE1 $1_{1-475}$ and cloned into the same
sites of pGS284-FXIE1kanlacZ thereby generating pGS284-FXMIE and pGS284-FXIE1 1-475, respectively. For verification, DNA sequence analysis was completed on all cloned PCR amplification products. Allelic exchange was performed through homologous recombination in E. coli strain GS500 as previously described (21, 48, 49). First, the BAC pFXIE1kanlacZ was generated by recombination of pFXwt with pGS284-FXIE1kanlacZ followed by selection for kanamycin resistance and LacZ expression. After that, the BACs $\mathrm{pFXIE} 1_{1-475}$ and pFXrvIE 1 were made through recombination of pFXIE1kanlacZ with pGS284-FXIE1 $1_{1-475}$ and pGS284-FXMIE, respectively, followed by selection for the loss of kanamycin resistance and LacZ expression. The identity and integrity of $\mathrm{pFXIE} 1_{1-475}$ and pFXrvIE 1 were verified in comparison to pFXwt by restriction fragment length and DNA sequence analyses (data not shown). All oligonucleotide sequences are listed in Table S1.

Cell- and serum-free virus stocks were produced upon electroporation of MRC-5 cells with BAC clones carrying wild-type (TNwt, FXwt, TBwt), revertant (FXrvIE1, TBrvIE1 $1_{1-475}$ ), or IE1 CTD-deficient $\left(\right.$ FXIE $_{1-475}$, TBIE1 $\left._{1-475}\right)$ genomes. Stocks of TNdIIE1 viruses were produced in a similar fashion, following electroporation of TetR-IE1 cells (40). All virus stocks were screened for mycoplasma contamination. Titers were calculated by qPCR-based absolute quantification of intracellular viral genome copies following infection of MRC-5 cells as described $(21,40)$ and by comparing the results to a standard curve based on amplifications from plasmid pCR-RPPH1UL54P (see above) mixed with salmon sperm DNA. For wild-type viruses, titers were also determined by standard plaque assay on MRC-5 cells. For mutant and revertant viruses, plaque forming units relative to wild-type titers were calculated from intracellular viral copy numbers. Infections were carried out at the indicated input multiplicities and for the indicated durations on (nearly) confluent MRC-5 cells.

Protein production, purification, and analysis. For protein production in E. coli, a single colony of the Rosetta strain (Novagen) transformed with pGEX-KG or derivatives was grown by shaking (220 revolutions per minute [rpm]) overnight at $28^{\circ} \mathrm{C}$ in Luria-Bertani medium containing ampicillin ( $50 \mu \mathrm{~g} / \mathrm{ml}$ ), chloramphenicol ( $20 \mu \mathrm{~g} / \mathrm{ml}$ ), and $2 \%$ glucose. On the next day, the culture was diluted to an optical density at $600 \mathrm{~nm}\left(\mathrm{OD}_{600}\right)$ of 0.1 with fresh prewarmed medium lacking glucose and further grown for $2-3 \mathrm{~h}$ at 220 rpm and $28^{\circ} \mathrm{C}$ to an $\mathrm{OD}_{600}$ of 0.6 . At this point, gene expression was induced by adding isopropyl- $\beta$-D-thiogalactopyranoside to a final concentration of $200 \mu \mathrm{M}$. Following a 6-h incubation at 220 rpm and $28^{\circ} \mathrm{C}$, cells were quickchilled on ice and collected by centrifugation $\left(\sim 2,500 \times \mathrm{g}, 15 \mathrm{~min}, 4^{\circ} \mathrm{C}\right)$. Bacteria were resuspended in $1 / 10$ culture volume ice-cold wash buffer ( 50 mM Tris- $\mathrm{HCl}[\mathrm{pH} 7.5], 150 \mathrm{mM}$ $\mathrm{NaCl}, 2 \mathrm{mM} \mathrm{MgCl} 2,1 \mathrm{mM}$ DTT, cOmplete EDTA-free Protease Inhibitor Cocktail [Roche]). After another round of centrifugation $\left(\sim 2,500 \times \mathrm{g}, 15 \mathrm{~min}, 4^{\circ} \mathrm{C}\right)$, the pellet was resuspended in $1 / 25$ culture volume ice-cold wash buffer containing 1 mM phenylmethylsulfonyl fluoride (added freshly). The suspension was snap-frozen in liquid nitrogen and stored at $-80^{\circ} \mathrm{C}$.

To purify GST and GST fusion proteins, bacteria suspended in wash buffer (see above) were thawed in a water bath at room temperature. For the subsequent workflow, ice-cold buffers and solutions were used, and all steps were carried out on ice or at $4^{\circ} \mathrm{C}$. Following addition of lysozyme $(150 \mu \mathrm{~g} / \mathrm{ml})$ and benzonase ( $25 \mathrm{U} / \mathrm{ml}$ ), the suspension was sonicated five times for 1 min using a Branson Sonifier 450 (duty cycle $80 \%$, output control 2) to facilitate cell lysis. The lysate was combined with $1 / 9$ volume wash buffer containing $10 \%$ Triton X-100, rotated for 30 min to solubilize proteins, and centrifuged $(20,000 \times \mathrm{g}, 30 \mathrm{~min})$. The affinity matrix was prepared by washing Glutathione Sepharose 4B (GE Healthcare) consecutively in ten bed volumes equilibration buffer ( 50 mM Tris- $\mathrm{HCl}[\mathrm{pH} 7.5], 150 \mathrm{mM} \mathrm{NaCl}, 2 \mathrm{mM} \mathrm{MgCl} 2$ ), 10 bed volumes blocking buffer (equilibration buffer with $2 \%$ bovine serum albumin) ( 1 h under rotation), and
another 10 volumes equilibration buffer. After that, 1.25 ml equilibrated matrix per $1,000 \mathrm{ml}$ culture volume and the supernatant from the bacterial lysate were combined and rotated for 2 h . The sample was then applied to a $10-\mathrm{ml}$ Pierce Centrifuge Column (Thermo Scientific), and the matrix was washed consecutively with 50 bed volumes low salt wash buffer ( 50 mM Tris- HCl [pH 7.5], $150 \mathrm{mM} \mathrm{NaCl}, 1 \mathrm{mM}$ dithiothreitol [DTT], $1 \%$ Triton X-100, 1 mM EDTA, cOmplete EDTA-free Protease Inhibitor Cocktail), 50 bed volumes high salt wash buffer ( 50 mM Tris- HCl [pH 7.5], $500 \mathrm{mM} \mathrm{NaCl}, 1 \mathrm{mM}$ DTT, $1 \%$ Triton X-100, 1 mM ethylenediaminetetraacetic acid (EDTA), cOmplete EDTA-free Protease Inhibitor Cocktail), and another 50 bed volumes low salt wash buffer. After the final washing step, one bed volume low salt wash buffer was added, the column was sealed, and the $50 \%$ slurry containing purified proteins was stored in ice until use. To remove the GST tag from GST-IE1 and GST-IE1 $1_{1-475}$, the protein-loaded matrix was washed with 50 bed volumes cleavage buffer (PBS with 1 mM DTT ), the column outlet was sealed, and one bed volume of cleavage buffer containing PreScission protease ( $50 \mathrm{U} / \mathrm{ml}$, GE Healthcare) was added. Protein cleavage was allowed to proceed in the sealed column for 16 h under rotation. After that, the flow-through containing IE1 or $\mathrm{IE}_{1-475}$ proteins was collected. Protein concentrations were calculated assuming absorption at 280 nm values of 0.396 or 0.409 for 1 $\mathrm{g} / 1,000 \mathrm{ml}(0.1 \%)$ IE1 or IE1 $1_{1-475}$, respectively.

For preparation of nucleosomes, H1299 cells grown to confluency were scraped on ice and collected in $15-\mathrm{ml}$ tubes by centrifugation $\left(500 \times \mathrm{g}, 5 \mathrm{~min}, 4^{\circ} \mathrm{C}\right)$. For the subsequent workflow, ice-cold buffers and solutions were used, and all steps were carried out on ice or at $4^{\circ} \mathrm{C}$. Cell pellets, each corresponding to one $10-\mathrm{cm}$ plate, were resuspended in 1 ml MNase lysis buffer ( 10 mM Tris- $\mathrm{HCl}[\mathrm{pH} 7.4], 10 \mathrm{mM} \mathrm{NaCl}, 3 \mathrm{mM} \mathrm{MgCl} 2,150 \mu \mathrm{M}$ spermine, $500 \mu \mathrm{M}$ spermidine, $0.5 \%$ IGEPAL CA-630) and vortexed while simultaneously adding another 4 ml MNase lysis buffer. Following a 5 -min incubation, samples were centrifuged $(300 \times \mathrm{g}, 5 \mathrm{~min})$, the supernatant
was removed completely, and nuclei were washed in $500 \mu \mathrm{l}$ MNase reaction buffer ( 10 mM Tris$\mathrm{HCl}[\mathrm{pH} 7.4], 15 \mathrm{mM} \mathrm{NaCl}, 60 \mathrm{mM} \mathrm{KCl}, 150 \mu \mathrm{M}$ spermine, $500 \mu \mathrm{M}$ spermidine). After that, nuclei were carefully resuspended in $100 \mu \mathrm{MNase}$ reaction buffer with $1 \mathrm{mM} \mathrm{CaCl} \mathrm{Cl}_{2}$ and prewarmed for exactly 5 min at $30^{\circ} \mathrm{C}$. Extra-nucleosomal DNA was digested by adding 100 U Nuclease S7 MNase from Staphylococcus aureus (Roche) diluted in MNase dilution buffer (5 mM Tris- $\mathrm{HCl}[\mathrm{pH} 7.4], 10 \mu \mathrm{M} \mathrm{CaCl}_{2}$ ). Following incubation for 10 min at $30^{\circ} \mathrm{C}$, reactions were stopped with 20 mM EDTA and 2 mM ethylene glycol tetraacetic acid. For coimmunoprecipitations, nucleosome preparations ( $120 \mu \mathrm{l}$ ) were combined with whole cell extracts prepared as described above.

Histones were purified by acid extraction from H1299 cell nuclei. Cells grown to confluency were scraped on ice and collected in $15-\mathrm{ml}$ tubes by centrifugation $(500 \times \mathrm{g}, 5 \mathrm{~min}$, $4^{\circ} \mathrm{C}$ ). For the subsequent workflow, ice-cold buffers and solutions were used, and all steps were carried out on ice or at $4^{\circ} \mathrm{C}$. Cell pellets, each corresponding to one $15-\mathrm{cm}$ plate, were resuspended in 1 ml hypotonic lysis buffer ( 10 mM Tris- $\mathrm{HCl}[\mathrm{pH} 7.5], 10 \mathrm{mM} \mathrm{NaCl}, 3 \mathrm{mM}$ $\mathrm{MgCl}_{2}, 10 \mathrm{mM}$ DTT, $0.5 \%$ IGEPAL CA-630, EDTA-free Protease Inhibitor Cocktail Set III). Then, 4 ml hypotonic lysis buffer were added while samples were concomitantly vortexed at medium speed. Following a $5-\mathrm{min}$ incubation, nuclei were collected by centrifugation $(500 \times \mathrm{g}, 5$ min ) and washed by repeating the consecutive $1-\mathrm{ml}$ and $4-\mathrm{ml}$ resuspension steps in hypotonic lysis buffer twice (without the 5 -min incubation in between). Following centrifugation ( $500 \times \mathrm{g}, 1$ min ), the supernatant was removed completely, the pellet was resuspended in 1 ml 200 mM $\mathrm{H}_{2} \mathrm{SO}_{4}$, and the nuclei were transferred to $1.5-\mathrm{ml}$ tubes. After that, samples were incubated for 16 $h$ on a rotator. Following extraction, samples were centrifuged $(20,000 \times \mathrm{g}, 30 \mathrm{~min})$ to remove insoluble debris, and $900 \mu 1$ supernatant were transferred to a new $1.5-\mathrm{ml}$ tube. Histones were precipitated by addition of trichloroacetic acid (TCA) to a final concentration of $35 \%$ and
overnight incubation at $-20^{\circ} \mathrm{C}$. After centrifugation $(20,000 \times \mathrm{g}, 15 \mathrm{~min})$, the protein pellet was washed by sonication (Branson Sonifier 450; 10 pulses, duty cycle $80 \%$, output control 8 ) in 1 ml acetone with 50 mM HCl and, subsequently, in 1 ml pure acetone at room temperature. After a final centrifugation step $(20,000 \times \mathrm{g}, 15 \mathrm{~min})$, pellets were dried at room temperature. For binding assays, histones were resuspended in an appropriate volume of reaction buffer by sonication (Branson Sonifier 450; 10 pulses, duty cycle $80 \%$, output control 8 ) and repeated pipetting.

For separation of histones into fractions containing either H2A-H2B or $\mathrm{H} 3-\mathrm{H} 4$, the purification protocol was extended by an ion exchange chromatography step (50) following acid extraction. Briefly, a 2-ml Pierce Centrifuge Column was filled with 1 ml Sulfopropyl-Sepharose Fast Flow (Sigma-Aldrich) and washed twice with 8.1 ml wash buffer I ( 50 mM Tris- $\mathrm{HCl}[\mathrm{pH}$ 8.0], $200 \mathrm{mM} \mathrm{NaCl}, 2 \mathrm{mM}$ EDTA). Concurrently, histone extracts (prepared as described above) from six $15-\mathrm{cm}$ dishes of H 1299 cells were pooled in a $50-\mathrm{ml}$ tube and combined with 2 volumes of 1 M Tris- $\mathrm{HCl}(\mathrm{pH} 8.0)$. After verifying the $\mathrm{pH}(\mathrm{pH} 7.0-8.0), 200 \mathrm{mM} \mathrm{NaCl}, 1 \mathrm{mM}$ DTT, and 2 mM EDTA were added, and the mixture was applied to the filled column. The column was washed with 8.1 ml wash buffer II ( 50 mM Tris- $\mathrm{HCl}[\mathrm{pH} 8.0], 500 \mathrm{mM} \mathrm{NaCl}, 2 \mathrm{mM}$ EDTA [pH 8.0]) and, subsequently, with the same volume of wash buffer III ( 50 mM Tris- HCl [ pH 8.0 ], 600 $\mathrm{mM} \mathrm{NaCl}, 2 \mathrm{mM}$ EDTA). For elution of H2A-H2B, 6.6 ml elution buffer I ( 50 mM Tris- $\mathrm{HCl}[\mathrm{pH}$ 8.0], $800 \mathrm{mM} \mathrm{NaCl}, 2 \mathrm{mM}$ EDTA) were added to the column, of which the first $600 \mu \mathrm{l}$ were discarded and six $1-\mathrm{ml}$ fractions were collected. Following two $8.1-\mathrm{ml}$ wash steps with elution buffer I, H3-H4 was eluted with 2.5 ml elution buffer II ( 50 mM Tris- $\mathrm{HCl}[\mathrm{pH} 8.0$ ], $2 \mathrm{M} \mathrm{NaCl}, 2$ mM EDTA) and collected in five $500 \mu$ l-fractions. A subset of histone fractions (determined by polyacrylamide-sodium dodecyl sulfate [SDS] gel electrophoresis and Coomassie Brilliant Blue staining, see below) were pooled and subjected to TCA precipitation as described above.

For protein analysis, samples were mixed with $2 \times$ loading buffer ( 100 mM Tris- $\mathrm{HCl}[\mathrm{pH}$ 6.8], $4 \%$ SDS, $20 \%$ glycerol, $0.2 \%$ bromphenol blue, $200 \mathrm{mM} \beta$-mercaptoethanol), denatured for 5 min at $95^{\circ} \mathrm{C}$, and separated in SDS-polyacrylamide gels that were either stained with Coomassie Brilliant Blue (PlusOne Coomassie Blue PhastGel R-350, GE Healthcare) according to the manufacturer's instructions, or subjected to immunoblotting including chemiluminescent detection (SuperSignal West Pico or SuperSignal West Femto, Thermo Scientific) as described (51). The following antibodies were used for protein detection following blotting: $\alpha$-Flag (M2, Sigma-Aldrich), $\alpha$-GAPDH (ab9485, Abcam), $\alpha$-HA (3F10, Roche), $\alpha$-H2A (ab13923, Abcam), $\alpha-\mathrm{H} 2 \mathrm{~B}(\mathrm{ab} 1790, \mathrm{Abcam}), \alpha-\mathrm{H} 3$ (ab1791, Abcam), $\alpha-\mathrm{H} 4$ (62-141-13, Upstate), $\alpha-\mathrm{IE} 1$ (1B12, [52]; ab30924 [IE1.G10], Abcam; 6E1, Santa Cruz), $\alpha$-IE1/IE2 (MAB810R, Merck Millipore), and horseradish peroxidase-coupled anti-mouse (115-036-003, Dianova), anti-rabbit (AP156P, Chemicon), or anti-rat (112-035-003, Dianova) secondary conjugates.

Protein binding and competition analysis. For co-immunoprecipitations, subconfluent H1299 cells on $10-\mathrm{cm}$ plates were transfected with $10 \mu \mathrm{~g}$ plasmid DNA using a calcium phosphate precipitation technique (53). Approximately 48 h post transfection, cells were stored at room temperature for 10 min and cross-linked by adding formaldehyde to a final concentration of $1 \%$ directly to the medium. Following a $5-\mathrm{min}$ incubation at room temperature, a glycine solution ( 125 mM final concentration) was added to each dish to terminate cross-linking. After another 5min incubation at room temperature, the medium was removed, and cells were washed twice with 10 ml ice-cold serum-free DMEM. For the subsequent workflow, ice-cold buffers and solutions were used, and all steps were carried out on ice or at $4^{\circ} \mathrm{C}$. Cells were scraped into 2 ml serumfree DMEM with EDTA-free Protease Inhibitor Cocktail Set III (Merck Millipore), and each dish
was washed three times with 2.5 ml serum-free DMEM for optimal cell recovery. After that, cells were centrifuged $(2,500 \times \mathrm{g}, 10 \mathrm{~min})$, and the medium was removed completely. The cell pellet was resuspended in 1 ml immunoprecipitation (IP) lysis buffer ( 50 mM Tris- HCl [ pH 7.5 ], 125 $\mathrm{mM} \mathrm{NaCl}, 500 \mu \mathrm{M}$ DTT, $0.5 \%$ IGEPAL CA-630, $1 \%$ Triton X-100, 5 mM EDTA, EDTA-free Protease Inhibitor Cocktail Set III), and the suspension was incubated for 5 min . After centrifugation $(12,000 \times \mathrm{g}, 1 \mathrm{~min})$, the pellet was washed in IP lysis buffer, recentrifuged $(12,000 \times \mathrm{g}, 1 \mathrm{~min})$, resuspended in IP lysis buffer, and incubated for 10 min . Then, the cell lysate was sonicated three times for 5 min in a Bioruptor UCD-200 (Diagenode; position "H", 30 s onoff cycle) to shear the chromatin. After that, insoluble debris was removed by centrifugation $(20,000 \times \mathrm{g}, 30 \mathrm{~min})$, and $900 \mu \mathrm{l}$ supernatant were transferred to a new $1.5-\mathrm{ml}$ tube. The following matrices were used for the subsequent immunoprecipitation reactions: Anti-Flag M2 Affinity Gel (Sigma-Aldrich), Monoclonal Anti-HA-Agarose (HA-7, Sigma-Aldrich), Mouse IgG-Agarose (Sigma-Aldrich), or Protein A Agarose/Salmon Sperm DNA (Merck Millipore). Before use, agarose beads were washed three times in 1 ml IP lysis buffer. To preclear the lysate, $100 \mu \mathrm{l}(20$ $\mu l$ bed volume) Mouse IgG-Agarose or Protein A Agarose/Salmon Sperm DNA were added, and the mixture was rotated for 1 h . Following centrifugation $(20,000 \times \mathrm{g}, 30 \mathrm{~min}), 50 \mu 1$ supernatant were removed to serve as input sample and $850 \mu$ l were transferred to a new $1.5-\mathrm{ml}$ tube. For reactions using Protein A Agarose/Salmon Sperm DNA, the lysate was incubated overnight with $\alpha-\mathrm{H} 3$ antibodies (ab1791, Abcam) or IgG from rabbit serum (Sigma-Aldrich). Then, $100 \mu \mathrm{l}$ (20 $\mu l$ bed volume) of the respective antibody-coupled or Protein A agarose matrix were added. After rotation for 1 h , samples were centrifuged $(100 \times \mathrm{g}, 1 \mathrm{~min})$, and the supernatant was removed completely. The protein-loaded matrix was resuspended in $100 \mu \mathrm{l}$ DNase buffer (Ambion) and reacted with $2 \mu \mathrm{l}(4 \mathrm{U})$ DNase I (Ambion) for 15 min at $25^{\circ} \mathrm{C}$. After that, 1 ml IP lysis buffer was
added, and the matrix was washed five times in the same buffer. Following the final centrifugation step $(100 \times \mathrm{g}, 1 \mathrm{~min})$, the pellet was resuspended in $45 \mu \mathrm{l} 1 \times$ loading buffer, and samples were heated ( 10 min for output and 5 min for input samples). Before electrophoresis, output samples were centrifuged $(16,000 \times \mathrm{g}, 5 \mathrm{~min})$, and only the supernatant was used for immunoblotting.

For GST pull-down assays, ice-cold buffers and solutions were used, and all steps were carried out on ice or at $4^{\circ} \mathrm{C}$. For each reaction, $20 \mu \mathrm{l}$ (bed volume) Glutathione Sepharose 4B (GE Healthcare) loaded with GST or GST fusion proteins were washed twice in $700 \mu$ l binding buffer ( 50 mM Tris- $\mathrm{HCl}[\mathrm{pH} 8.0], 150 \mathrm{mM} \mathrm{NaCl}, 1 \mathrm{mM}$ DTT, $10 \%$ glycerol, $0.5 \%$ Triton X-100, EDTA-free Protease Inhibitor Cocktail Set III). Acid-extracted histones from one half $15-\mathrm{cm}$ dish of H1299 cells in $300 \mu \mathrm{l}$ binding buffer were subjected to one 10 min and two 5 min centrifugations $(20,000 \times \mathrm{g})$ to remove insoluble debris. The histone solution was subsequently combined with the washed protein-loaded sepharose matrix, and $10 \%$ of the total volume was removed to serve as input sample. The suspension was rotated for 90 min to facilitate binding. After that, the matrix was washed five times in $700 \mu \mathrm{l}$ binding buffer, resuspended in $100 \mu \mathrm{l}$ $1 \times$ loading buffer, heated, and analyzed.

To analyze competition between IE1 and LANA for nucleosome/histone binding, synthetic peptides encompassing KSHV LANA residues 5 to 22 (LANA-CTD: GMRLRSGRSTGAPLTRGS) or a mutant amino acid sequence deficient for histone binding (LANA-CTD*: GMRAAAGRSTGAPLTRGS) were purchased from Thermo Scientific and dissolved in water. IE1 and $\mathrm{IE}_{1-475}$ proteins were derived from the respective GST fusion proteins by cleavage with PreScission protease (GE Healthcare). Acid-extracted histones in binding buffer were preincubated for 1 h with various concentrations of LANA-CTD or LANACTD* ( 1 mM stock solution), IE1 ( $95 \mu \mathrm{M}$ stock solution), or IE $_{1-475}$ ( $83 \mu \mathrm{M}$ stock solution).

After that, the samples were centrifuged $(20,000 \times \mathrm{g}, 15 \mathrm{~min})$, and the supernatant was reacted with the respective GST or GST fusion proteins coupled to Glutathione Sepharose 4B as described above.

For protein quantification, bands were scanned at 72 dots per inch and subjected to densitometry using Scion Image 4.0.2 software (Scion Corporation) including the GelPlot2 extension.

Immunofluorescence and microscopy. Subconfluent H1299 or MRC-5 cells grown on sterile coverslips in 6-well dishes were transfected with $5 \mu \mathrm{~g}$ plasmid DNA using a calcium phosphate precipitation technique (53). Alternatively, MRC-5 cells were mock- or hCMVinfected as described in Supplemental Material. Approximately 48 h post transfection or infection, cells were washed three times with phosphate-buffered saline (PBS) containing 0.05\% Tween 20 (PBS-T) and fixed with ice-cold methanol for 20 min at $-20^{\circ} \mathrm{C}$. After three 5 -min washes with PBS-T, samples were blocked for 1 h in PBS-T containing 2\% bovine serum albumin (BSA) and reacted for 1 h with the respective primary antibodies in a humidity chamber. The primary antibodies used for immunofluorescence were $\alpha$-EGFP (ab290, Abcam) or $\alpha$-IE1 (ab30924 [IE1.G10], Abcam; sc-69834 [6E1], Santa Cruz). Following three 5-min washes with PBS-T and a 1-h incubation with the appropriate Alexa Fluor 488- and Alexa Fluor 594conjugated secondary antibodies (Life Technologies) and $0.2 \mu \mathrm{~g} / \mathrm{ml}$ 4',6-diamidino-2phenylindole (DAPI) (Roche), coverslips were mounted on glass slides using ProLong Gold (Life Technologies). Slides were analyzed using a Keyence BZ 9000 (Generation II) or a Leica DMRX epifluorescence microscope equipped with a digital camera system (Retiga, Q-Imaging), and images were acquired and processed using BZ II Analyzer (Keyence) or Image-Pro Plus (version
6.2) (Q-Imaging) and Adobe Photoshop CS4 software. The extent of overlap between pixels in the green and blue channels was quantified by calculating Pearson's correlations from autocontrasted eight bit images using ImageJ software (National Institutes of Health) and the Colocalization_Finder (version 1.2) plugin (http://rsb.info.nih.gov/ij/plugins/colocalizationfinder.html).

Molecular modeling. Homology modeling was performed using the PERMOL module (54) implemented in the AUREMOL package (55). The 16 carboxy-terminal residues (amino acids 476-491) of hCMV (Towne) IE1 were aligned with 14 amino-terminal residues (amino acids 4-17) of KSHV LANA using a program based on the Needleman-Wunsch algorithm contained in PERMOL. The alignment was confirmed with other programs including ClustalW2 (http://www.ebi.ac.uk/tools/msa/clustalw2) and EMBOSS Stretcher (http://www.ebi.ac.uk/tools/psa/emboss_stretcher), respectively. An alternative alignment was produced by just one of all tested programs (LALIGN; http://www.ebi.ac.uk/tools/psa/lalign). Other possible alignments were excluded as they did not involve the nucleosome binding motif (GMRLRSG) of the LANA CTD. As a template for homology modeling, we used the x-ray structure of the $\mathrm{LANA}_{4-17}$-nucleosome complex (12) (PDB: 1zla). The modeling was restricted to the interaction site of the LANA peptide with histones H2A and H2B, i.e., LANA amino acids 417, H2A amino acids 14-107, and H2B amino acids 30-122 could evolve using restrained molecular dynamics while the remaining part of the histone complex was held rigid during the calculations. For the modeling, the LANA peptide was replaced by the IE1 CTD using either of the two reasonable amino acid sequence alignments. In a second step, we used PERMOL to generate interatomic distance restraints, dihedral angle restraints, and hydrogen bonds from the H2A-H2B/IE1 CTD model template based on the degree of sequence conservation between the

LANA and IE1 CTDs. With this set of restraints, 1,000 structures were calculated per each model using the molecular dynamics program Crystallography \& NMR System (56, 57). The twenty best structures in terms of total energy were used for explicit water refinement (58). After the water refinement, a bundle of the ten lowest energy structures was selected for each of the two models.

## RESULTS

IE1 interacts with nucleosomes in a nucleic acid-independent fashion. We started the work by employing immunoprecipitation-immunoblotting analysis to investigate whether IE1 and other nuclear localized CMV proteins are physically associated with nucleosomes. For the first set of binding assays, extracts from cells transfected either with empty vector or with plasmids encoding epitope-tagged hCMV IE1, murine cytomegalovirus (mCMV) IE1 (mIE1), hCMV IE2, and hCMV pp71 were combined with exogenous nucleosomes prepared by micrococcal nuclease (MNase) digestion of human cell nuclei. Readily detectable amounts of core histones from all four classes (H2A, H2B, H3, and H4) were found to co-precipitate with IE1, while much smaller amounts were detected with IE2. Very little, if any, histone binding was observed in the mIE1, pp71, and empty vector transfections. Likewise, a non-specific antibody did not precipitate any appreciable amounts of core histones (Fig. 1A). In a second round of experiments, we checked for co-precipitation of endogenous nucleosomes solubilized by sonication with epitope-tagged IE1, mIE1, IE2, and pp71. Under these conditions, specific core histone binding could only be demonstrated for IE1, but not for any of the other viral proteins under investigation (Fig. S1). Importantly, IE1 was found to specifically interact with endogenous core histones not only in plasmid-transfected but also in hCMV-infected cells (Fig. 1B).

To confirm the results obtained by immunoprecipitation-immunoblotting in another type of binding assay, we expressed IE1 fused to glutathione S-transferase (GST) in Escherichia coli and affinity-purified the protein on glutathione sepharose beads. GST-IE1 beads and beads loaded with only GST or no protein (empty beads) were subsequently reacted with acid-extracted histones, and samples were analyzed by electrophoresis in polyacrylamide gels stained with

Coomassie Brilliant Blue. The four core histones were found to interact with GST-IE1 at an approximately equimolar ratio, while only minor binding to GST or empty beads was observed in these assays (Fig. 1C). IE1 is not believed to bind DNA or RNA directly, and acid-extracted histone preparations are not supposed to contain intact nucleic acids. However, to fully rule out the possibility that the observed IE1-histone interactions are mediated through DNA or RNA, the pull-down assays were repeated in the presence of excess amounts of nucleases (DNase I and RNase A). As expected, the results obtained from DNase- and RNase-treated samples were virtually indistinguishable from those obtained in the absence of nucleases (Fig. 1C).

Taken together, the results from our in vivo and in vitro interaction assays demonstrate that IE1 specifically binds to human nucleosome cores, most likely through direct interaction with histones.

IE1 interacts with core histones via two separable regions with distinct binding specificities. To investigate whether core histones interact with IE1 residues previously shown to be required for chromosome association (22), we constructed plasmids encoding GST fused either to a carboxy-terminally truncated IE1 lacking the CTD (GST-IE1 $1_{1-475}$ ) or to an aminoterminally truncated IE1 consisting of only the CTD (GST-IE1 ${ }_{476-491}$ ). We also generated a plasmid encoding GST fused to the KSHV LANA amino-terminal CTD (GST-LANA ${ }_{5-22}$ ) (59, 60), which was shown to bind to the H2A-H2B dimer of the nucleosome (12, 61) (Fig. 2A). Following expression in E. coli, the GST fusion proteins were used in pull-down assays with acid-extracted histone preparations as described above for wild-type GST-IE1 (see Fig. 1C). With GST-IE $1_{1-475}$, a reduction in H 2 A and H 2 B binding was evident compared to the full-length protein, whereas H3 and H4 binding was not negatively affected. Conversely, GST-IE1 $1_{476-491}$ and GST-LANA $_{5-22}$ did not specifically interact with H3 and H4. Instead, both GST-IE1 ${ }_{476-491}$ and

GST-LANA $_{5-22}$ displayed selective affinity for H 2 A and H 2 B . The interaction between H2AH2B and GST-IE1 ${ }_{476-491}$ was less efficient compared to full-length GST-IE1, but about equally efficient compared to GST-IE1 $1_{1-475}$ and GST-LANA ${ }_{5-22}$. No interaction between any of the GST proteins and linker histone H1 was detected (Fig. 2B). Notably, CTD-mediated complex formation between IE1 and H2A or H2B was also observed in co-immunoprecipitations from cells arrested in interphase (G0 phase), indicating that nucleosome targeting by the viral protein is not restricted to mitosis (Fig. S2).

To discriminate between direct and indirect core histone interactions, acid-extracted histones were further purified and separated into fractions highly enriched for either H2A-H2B dimers or H3-H4 dimers/tetramers. As predicted from the preceding experiments (see Fig. 2B), GST-IE $_{1-475}$ and GST-IE1 $1_{476-491}$ displayed H2A-H2B binding comparable to GST-LANA ${ }_{5-22}$ but less efficient compared to full-length GST-IE1. By contrast, GST-IE1 and GST-IE1 $1_{1-475}$ were equally efficient in binding to H3-H4. Finally, for GST-IE1 ${ }_{476-491}$ and GST-LANA ${ }_{5-22}$ no H3-H4 interaction above background was observed (Fig. 2C).

The results from these experiments allow for several conclusions: (i) IE1 binds to core histones through at least two physically separable (and therefore independent) interaction surfaces, i.e., the CTD and unspecified sequences located upstream from the carboxy-terminus; (ii) the CTD selectively binds to H2A-H2B dimers through direct interaction, while the upstream histone binding domain directly binds to both H2A-H2B and H3-H4 dimers/tetramers with a preference for $\mathrm{H} 3-\mathrm{H} 4$; (iii) there are striking similarities between nucleosome binding by the IE1 and LANA CTDs.

## Alanine scanning mutagenesis identifies a discrete nucleosome binding motif within

 the IE1 CTD. To gain further insight into the physical requirements of IE1-nucleosome complexformation, we decided to determine which individual CTD residues contribute to the interaction. For this purpose, we performed alanine scanning mutagenesis replacing each of the 16 amino acids comprising the IE1 CTD with alanine (except for A489, which was replaced by glycine) (Fig. 3A). All mutant CTDs were expressed as GST fusion proteins in E. coli and used in pulldown assays with acid-extracted histones. The IE1 CTD pulled down all four core histones in these assays, most likely because the experimental conditions (i.e., higher histone concentrations leading to a larger proportion of octamers compared to Fig. 2B) allowed not only for direct (H2A-H2B) but also for indirect (H3-H4) interactions. Again, no binding to linker histone H1 was observed. Interestingly, only four CTD residues (H481, M483, T485, and R486) proved to be essential for histone binding. In addition, six amino acids (S479, T480, P482, V484, S487, and K488) turned out to augment the interaction significantly. In contrast, mutation of all residues upstream of S479 (G476, G477, and K478) and downstream of K488 (A489, D490, and Q491) had no obvious adverse effect on CTD-histone complex formation. In fact, the D490A exchange appeared to even enhance histone binding compared to the wild-type CTD (Fig. 3B-C).

In order to link the in vitro histone binding results to cellular chromosome association, we also expressed the wild-type and mutant CTD peptides as fusion proteins with amino-terminal EGFP in human cells. Co-staining of the EGFP-CTD proteins with mitotic DNA revealed that each of the same four residues shown to be essential for histone binding (H481, M483, T485, and R486) is also indispensable for chromosome attachment (Fig. 4A B). Alanine substitution of all four essential CTD residues or individual substitution of M483 also abolished mitotic chromatin association of IE1 in the context of the full-length protein (Fig. 4C). Moreover, in agreement with the binding results, individual exchange of S479, T480, P482, V484, S487, and K488 was linked to an intermediate phenotype, while mutation of residues at the edges of the IE1 CTD had no
significant negative (G476, G477, K478, A489, and Q491) or even positive (D490) effects on chromosome association (Fig. 4A-B).

These results identify a ten-amino-acid nucleosome binding motif (NBM: STHPMVTRSK) within the IE1 CTD, of which amino acids H481, M483, T485, and R486 are individually essential for nucleosome core targeting and chromosome attachment (Fig. 4D).

Histone binding by the IE1 CTD is directed by acidic residues in H2A. In addition to identifying the viral determinants of IE1-nucleosome complex formation, we set out to probe the histone-specific contributions. Much of the LANA-nucleosome interaction is mediated by negatively charged residues in H2A composing the acidic pocket (12). Given the similarities in histone binding between the LANA and IE1 CTDs (see Fig. 2), each of the nine negatively charged amino acids found in H2A (including acidic pocket residues E56, E61, E64, D90, E91, and E92) (Fig. 5A) was individually replaced with alanine. Additionally, we constructed two triple mutants where H2A residues E61, E64, and D90 or D90, E91, and E92 were simultaneously changed to alanine. Subsequently, human cells were transfected with plasmids encoding epitope-tagged wild-type or mutant H 2 A , and pull-down assays with acid-extracted histones and GST-IE1 ${ }_{476-491}$ were conducted (Fig. 5B). Interestingly, only mutations in acidic pocket residues E56, E61, E64, and D90 and the two triple substitutions proved to abolish IE1H2A binding while all other mutations (E41A, D72A, E91A, E92A, and E121A) had little, if any, effect on this interaction.

To confirm these results in the context of the full-length IE1 protein, we performed additional immunoprecipitation-immunoblotting assays (Fig. 5C-D). Again, the E41A, D72A, E91A, E92A, and E121A substitutions did not diminish (but rather enhanced) IE1 binding relative to wild-type H 2 A . However, we reproducibly found reduced binding between the viral
protein and H2A mutants E56A, E61A, E64A, D90A, and D90A/E91A/E92A. In addition, the E61A/E64A/D90A mutant exhibited highly impaired IE1 binding. As expected, neither of the histone mutants was completely defective for binding to the viral protein, most likely due to the second histone binding domain located upstream of the CTD (see Fig. 2B-C). Correspondingly, IE1 $1_{1-475}$ retained some affinity for H2A (Fig. 5C-D).

These results demonstrate that several negatively charged H2A residues (E56, E61, E64, and D90) composing the nucleosomal acidic pocket, but not acidic residues outside the pocket, selectively direct the interaction with the IE1 CTD.

The IE1 and LANA CTDs compete for binding to nucleosome cores and chromosomes. Our results indicate that IE1 targets human chromatin via interaction between its CTD and the acidic pocket formed by H2A-H2B on nucleosome cores (see Fig. 2-5), which closely resembles the situation described for LANA (12). To further test the idea that the IE1 and LANA CTDs target the same nucleosomal surface, we asked whether the presence of the IE1 CTD is compatible with or competitive to nucleosome binding by the LANA CTD. First, we utilized a competition pull-down assay to address this question. GST-LANA ${ }_{5-22}$ was reacted with acid-extracted histone octamers and increasing molar ratios of purified IE1. As observed beforehand for IE1 (see Fig. 3B), histone binding by LANA extended to all four core histone species under these conditions. However, IE1 diminished complex formation between the LANA CTD and core histones in a dose-dependent manner (Fig. 6A). Compared to full-length IE1, the CTD-deficient protein ( $\mathrm{IE1}_{1-475}$ ) was much less efficient in competing with GST-LANA ${ }_{5-22}$ for histone binding (Fig. 6B). Very similar results were obtained when a synthetic peptide encompassing the LANA CTD (LANA-CTD) was used to compete with binding between GSTIE1 $_{476-491}$ and core histones, while a mutant peptide (LANA-CTD*) had no effect (Fig. 6C).

To gain in vivo support for our assumption that the IE1 and LANA CTDs compete for binding to nucleosomes, we expressed HA-tagged IE1 and LANA ${ }_{5-22}$ fused to EGFP in human cells and examined their localization by immunofluorescence microscopy. In mitotic cells, both EGFP-LANA $_{5-22}$ and HA-IE1 predominantly localized to condensed chromatin when expressed individually (with HA or EGFP, respectively) conforming to previous observations (e.g., 12, 20, $22,24,59)$. However, simultaneous expression of the two proteins resulted in partial release of EGFP-LANA $_{5-22}$ and almost complete displacement of HA-IE1 from mitotic chromatin. As expected, HA-IE1 lacking the CTD (HA-IE1 $1_{1-475}$ ) did not attach to chromosomes (Fig. S3). These results strongly suggest that IE1 and LANA share the same binding site on the nucleosome.

## The IE1 CTD is predicted to form a $\beta$-hairpin recognizing the acidic pocket on the

 nucleosomal surface. The notion of a shared binding site for IE1 and LANA on the nucleosome also suggests that key residues responsible for CTD-histone interaction may be conserved between the two viral proteins. Therefore, we generated alignments between the IE1 and LANA CTD sequences. The algorithm implemented in PERMOL $(54,62)$ and most other tested programs (e. g., ClustalW2, European Bioinformatics Institute) produced an alignment with three identical residues, one conserved exchange, and two semi-conserved substitutions between LANA $_{4-17}$ and IE1 $1_{476-491}$ (Fig. 7A). However, the same number of identical residues was also found with an alternative alignment (Fig. S4A) generated by another program (LALIGN, European Bioinformatics Institute). The two alignments differ mainly in the way the RS sequence (R486-S487) in the IE1 CTD is positioned relative to either of two RS sequences (R9-S10 and R12-S13) in the LANA CTD. Other possible alignments were excluded as they did not involve the LANA residues known to be required for nucleosome binding (12).Based on the two most likely alignments and the available x-ray structure of the LANA amino-terminal peptide bound to the nucleosome core (Protein Data Bank [PDB]: 1zla), molecular dynamics-based homology modeling of the IE1 CTD-histone complex was performed. From the patterns of hydrogen bonds, interatomic distances, and dihedral angles $(54,62)$ two sets of restraints (one for each alignment) were created and used to calculate 1,000 structures by restrained simulated annealing. The ten best structures each in terms of lowest total energy were refined in explicit water resulting in structural bundles (Fig. 7B and Fig. S4B). The results suggest that the IE1 CTD can adopt a $\beta$-hairpin (two antiparallel $\beta$-strands connected by a reverse turn) resembling the LANA CTD structure. The structural bundle deduced from the first of the two alignments is well defined with a backbone root-mean-square deviation (RMSD) of 0.038 nm (Fig. 7B). In this model, the $\beta$-hairpin formed by the IE1 CTD is stabilized by four main chain intramolecular hydrogen bonds, and there are ten intermolecular hydrogen bonds between CTD residues and histones $\mathrm{H} 2 \mathrm{~A}-\mathrm{H} 2 \mathrm{~B}$ including amino acids forming the acidic pocket (Fig. 7C). A three-dimensional representation of this model indicates excellent shape and charge complementarity between the IE1 CTD and the acidic pocket formed by $\mathrm{H} 2 \mathrm{~A}-\mathrm{H} 2 \mathrm{~B}$ including H2A residues E56, E61, E64, and E92 (Fig. 7D-E and Movie S1). The model derived from the second alignment is structurally much less well defined exhibiting a backbone RMSD of 0.200 nm (Fig. S4B). Here, the CTD engages in only three intra- and five intermolecular hydrogen bonds (Fig. S4C).

Although both interaction models largely comply with our in vitro and in vivo data, the in silico results and conclusions from mutagenesis experiments (see Discussion) favor the model shown in Fig. 7.

The IE1 CTD is dispensable for productive replication of "clinical" hCMV strains. To address how IE1-nucleosome interaction may impact the course and outcome of infection, BAC clones of the hCMV low passage strains TB40E (TBwt) and FIX (FXwt) were used to construct mutant viruses specifically lacking the IE1 CTD (TBIE1 $1_{1-475}$ and $\mathrm{FXIE}_{1-475}$, respectively). We also generated "revertant" viruses (TBrvIE1 1-475 and FXrvIE1) to control for inadvertent genetic changes. The IE1 1-475 proteins expressed from the mutant genomes were detected at kinetics and steady-state levels comparable to full-length IE1 (Fig. 8A-B), and the mutant proteins were confirmed to be inactive for chromosome association (Fig. 8C-D) in hCMV-infected cells.

Following infection of permissive fibroblast cells (MRC-5), two independent clones each of TBIE1 $_{1-475}$ and FXIE1 $1_{1-475}$ did not exhibit significantly altered replication compared to the corresponding wild-type and revertant strains, neither at high nor low input multiplicities, as determined by quantification of extracellular viral DNA and infectious particles (Fig. 9). These findings are consistent with results from a recent study testing a CTD-deleted mutant of the hCMV high passage strain Towne (23). Thus, nucleosome targeting by IE1 appears to be entirely dispensable for normal productive hCMV infection in fibroblasts suggesting a function during non-productive infection and/or infection of other cell types (see Discussion).

## DISCUSSION

Structural aspects of the IE1-nucleosome interaction. Nucleosomes are the repeating centerpieces of chromatin (reviewed in 3, 4). Within the nucleosome core, the disordered histone tail domains are known to engage in interactions with numerous different proteins, while the folded regions are believed to primarily function in compacting and constraining the DNA. However, the nucleosome surface is highly contoured and differentially charged (1, 2). The most distinctive feature of this surface is the acidic pocket, a negatively charged and concave patch generated by several highly conserved glutamate and aspartate residues contributed by histone H2A and, to a lesser extent, H2B (reviewed in 63, 64). In fact, the acidic pocket is the only negatively charged area on the otherwise positive or hydrophobic nucleosomal surface. The pocket serves no apparent role in maintaining the structure of the nucleosome, but is specifically recognized by histone H 4 tails of adjacent nucleosomes $(1,2)$ and an increasing number of nonhistone cellular and viral proteins. The first protein, besides histone H4, reported to bind to the acidic pocket was LANA encoded by the $\gamma$-herpesvirus KSHV (12). Subsequently, human interleukin 33 (IL-33) (61), Drosophila melanogaster regulator of chromosome condensation 1 (RCC1) (65), human high-mobility group nucleosomal 2 (HMGN2) protein (66), and Saccharomyces cerevisiae silent information regulator 3 (Sir3) (67) were all shown or predicted to interact with the acidic pocket of the nucleosomal core. Furthermore, Foamy virus groupspecific antigen (Gag) and Borna disease virus ribonucleoprotein (RNP) were proposed to bind to host chromosomes via H2A-H2B $(68,69)$.

The present study identifies the first $\beta$-herpesvirus protein targeting the acidic pocket on the nucleosome. Previous work has demonstrated that the hCMV IE1 protein attaches to human
mitotic chromosomes through a CTD located at the carboxy-terminus (20, 22, 24). However, the mechanism of interaction has not been addressed. Although hCMV encodes several chromatinassociated proteins (e.g., 70, 71; reviewed in 72-76), nucleosome binding appears to be a rather unique feature of IE1. For instance, the hCMV IE2 protein is known to interact with DNA (e.g., 77-80), histones H3-H4 (81), and several histone-associated proteins (e.g., 51, 81-83); however, IE2 neither associates with condensed chromatin $(21,25)$ nor with nucleosomes (this work), at least not to the same extent as IE1. Surprisingly, even mIE1 has little affinity for nucleosomes and does not co-localize with mitotic chromatin (21, 84 and this work) despite reportedly binding to DNA and core histones (85, 86). Accordingly, IE1 orthologs of known rodent CMVs (including mCMV and rat CMV strains) do not seem to exhibit functional CTD sequences (data not shown). However, CTD and NBM sequences are highly conserved across IE1 proteins of primate CMVs (Fig. 10) (22). The African green monkey CMV IE1 ortholog has also been shown to associate with metaphase chromosomes (29). At the same time, sequence similarity across the full-length orthologous IE1 proteins is limited (Fig. 10). Thus, any available evidence points to nucleosome targeting being a primate-specific viral adaptation and a distinguishing feature of primate CMV IE1 proteins.

Our results indicate that the IE1 NBM directly and selectively recognizes the nucleosome core through the H2A-H2B dimer. In fact, IE1 does not detectably interact with linker histone H 1 , and nucleic acids are not required for nucleosome binding by the viral protein. The latter finding matches the long-standing assumption that hCMV IE1 does not directly bind to DNA (86), although our data do not exclude this possibility. Despite the fact that the CTD is sufficient for H2A-H2B binding, nucleosome core interaction, and chromosome association, histone binding by IE1 is clearly not restricted to the carboxy-terminal domain. Instead, another histone binding region, which functions independently from the CTD/NBM, must exist upstream of
amino acid 476. In contrast to the NBM, this region directly binds to all four core histones with a preference for $\mathrm{H} 3-\mathrm{H} 4$. The fact that all tested H2A mutants retain some affinity for full-length IE1 suggests that the upstream histone binding domain may interact with $\mathrm{H} 2 \mathrm{~A}-\mathrm{H} 2 \mathrm{~B}$ residues outside the acidic patch. It is tempting to speculate that negatively charged residues within three proximate acidic stretches (termed acidic domains 1 to 3, AD1-AD3) (21) between amino acids 373 and 475 of IE1 might engage in electrostatic interactions with basic residues of the $\mathrm{H} 3-\mathrm{H} 4$ tetramer and the H2A-H2B dimers. Moreover, the observation that $\mathrm{IE} 1_{1-475}$ does not associate with chromosomes and is not required for nucleosome interaction suggests that the upstream histone binding region may interact with "free" histones rather than nucleosomes.

In most published cases of interactions with the nucleosomal acidic pocket (H4, LANA, IL33, RCC1, and HMGN2), arginine (and serine) containing linear motifs within conformationally flexible protein regions contribute to H2A binding. Our work identifies the ten-amino-acid sequence STHPMVTRSK to be this motif in IE1 (NBM). Results from proton nuclear magnetic resonance spectroscopy suggest that the IE1 CTD is highly mobile and that this domain is natively unstructured (data not shown), as has been previously predicted (21). Nonetheless, our results strongly suggest that the IE1 CTD forms a loop connecting two hydrogen-bonded antiparallel $\beta$-sheets ( $\beta$-hairpin), at least when complexed with H2A-H2B ("induced fit"). The predicted IE1 $\beta$-hairpin closely resembles the structure previously reported for the complexed LANA CTD (12). Consequently, the mode of interaction with nucleosomes is strikingly similar for IE1 and LANA; this is not only evident from our binding and competition experiments, but also from comparisons between our preferred model and the known crystal structure of the IE1 and LANA CTD-nucleosome complexes, respectively. According to the published structure (12), LANA $_{4-17}$ interacts with E61, E64, D90, and E92 of H2A (and several residues of H2B).

Likewise, our preferred model displays interactions between IE1 ${ }_{476-491}$ and H2A E61, E64, and E92 (and H2B). In addition, substitution of H2A D90 has a strongly adverse effect on IE1 binding that cannot be directly inferred from the proposed hydrogen bond patterns. However, the imidazole ring of IE1 H 481 is expected to be positively charged in the complex and may thus be involved in an electrostatic interaction with the nearby negatively charged side chain of H 2 A D90. Most likely, the D90A exchange also alters the geometry of the IE1 H481 binding site within the acidic pocket. Interestingly, our model predicts an additional interaction of IE1476-491 with H2A E56 which has not been described for LANA. The importance of E56 for the IE1nucleosome interaction is reinforced by our mutational analyses. Moreover, the fact that E56 is not predicted to contribute to H2A-IE1 binding by our alternative model adds further experimental support in favor of the preferred model. Taken together, our structural data indicate that LANA and IE1 target nucleosomes through molecular interactions that are highly similar, albeit not identical.

Potential functions of the IE1-nucleosome interaction. Our structural analyses strongly suggest that the IE1 CTD has specifically evolved to fit the acidic pocket of the nucleosome, and the CTD/NBM sequences are highly and selectively conserved through primate CMV evolution. These findings clearly point to an important role of nucleosome targeting by IE1 in hCMV infection. However, no such role has been reported so far.

Our prior work has demonstrated that nucleosomes are not confined to cellular chromatin, but also form on hCMV nuclear DNA (87-89). We have also recently shown that global nucleosome occupancy and dynamics across hCMV genomes are largely controlled by IE1dependent mechanisms (88). Thus, IE1 may target nucleosomes for active remodeling of viral and/or cellular chromatin. Notably, interaction between the acidic pocket contributed by H2A-

H2B and a positively charged region of the histone H 4 tail from an adjacent nucleosome has been implicated in the formation of higher-order chromatin structures $(90,91)$. The H 4 tail has no significant sequence similarity with the IE1 or LANA CTDs (data not shown) and seems to adopt a different conformation compared to the viral peptides. Moreover, the binding sites of LANA (and hence also of IE1) and H4 in the acidic pocket do not overlap (2, 12). Nonetheless, the available structures and models predict that IE1 and LANA may displace the H 4 tail from the pocket raising the possibility that the viral proteins might adversely affect chromatin condensation. Conceivably, global chromatin decondensation may serve as a mechanism through which viruses enhance permissiveness of the cellular and/or viral genome to transcriptional activation and/or other DNA-based processes. Luger and colleagues have examined the effect of LANA CTD binding on folding and self-association of nucleosome arrays. Against expectations, they found that LANA stabilizes self-association of nucleosomes and promotes cellular heterochromatin formation (92). However, these findings somewhat conflict with other reports (e.g., 93). Likewise, IL-33 appears to regulate chromatin compaction by promoting nucleosomenucleosome interactions (61). It remains to be determined whether IE1 has any positive or negative effects on higher-order chromatin structure.

The CTD has been shown to be entirely dispensable for complementing the defective replication of an IE1-deficient mutant hCMV (Towne) in human fibroblasts (22). Moreover, mutant viruses of both laboratory-adapted and "clinical" hCMV strains expressing IE1 $1_{1-475}$ instead of the full-length protein do not display any obvious phenotypic differences compared to the parental wild-type viruses in these cells (23 and this work). Thus, nucleosome binding by IE1 appears to be irrelevant for hCMV productive infection in fibroblasts. However, IE1-nucleosome interaction may serve an important function in cell types supporting non-productive (latent) hCMV infections. More than a decade ago, it was first reported that LANA tethers KSHV
episomes to host mitotic chromosomes $(13,94)$, and LANA turned out to be necessary and sufficient for KSHV episome persistence in the absence of other viral genes. By bridging KSHV DNA and host chromosomes, LANA facilitates nuclear retention and segregation of viral episomes to daughter nuclei during viral latency (reviewed in 95). Very similar mechanisms are used by EBNA1 of EBV and the early 2 (E2) proteins of human and bovine papillomaviruses, which also tether their respective genomes to cellular chromosomes for efficient maintenance during cell division (reviewed in 96). As opposed to other DNA viruses, including both $\alpha$ - and $\gamma$ herpesviruses, the mechanism of viral genome persistence during latency has remained a mystery in any of the $\beta$-herpesviruses. Thus it is highly tempting to speculate that the IE1-nucleosome interaction described in this work may contribute to hCMV genome tethering and maintenance.

## ACKNOWLEDGMENTS

We would like to thank Robert Eisenman (Seattle, USA), Roger Everett (Glasgow, UK), Ronald Hay (Dundee, UK), Christian Sinzger (Ulm, Germany), Karsten Tischer (Berlin, Germany), and Dong Yu (St. Louis, USA) for important reagents, Ines Tschertner (Regensburg, Germany) for expert technical assistance, and Aloys Schepers (Munich, Germany) and Einat Zalckvar (Rehovot, Israel) for helpful comments.

This work was supported by grants from the Deutsche Forschungsgemeinschaft (NE791/22), the Human Frontier Science Program (RGY0071/2008), the Bayerische Forschungsstiftung, and by intramural funds from the Institute for Medical Microbiology and Hygiene.

## REFERENCES

1. Davey CA, Sargent DF, Luger K, Mäder AW, Richmond TJ. 2002. Solvent mediated interactions in the structure of the nucleosome core particle at $1.9 \AA$ resolution. J. Mol. Biol. 319:1097-1113.
2. Luger K, Mäder AW, Richmond RK, Sargent DF, Richmond TJ. 1997. Crystal structure of the nucleosome core particle at $2.8 \AA$ resolution. Nature 389:251-260.
3. Luger K, Dechassa ML, Tremethick DJ. 2012. New insights into nucleosome and chromatin structure: an ordered state or a disordered affair? Nat. Rev. Mol. Cell Biol. 13:436-447.
4. Andrews AJ, Luger K. 2011. Nucleosome structure(s) and stability: variations on a theme. Annu. Rev. Biophys. 40:99-117.
5. Sears J, Ujihara M, Wong S, Ott C, Middeldorp J, Aiyar A. 2004. The amino terminus of Epstein-Barr Virus (EBV) nuclear antigen 1 contains AT hooks that facilitate the replication and partitioning of latent EBV genomes by tethering them to cellular chromosomes. J. Virol. 78:11487-11505.
6. Kapoor P, Frappier L. 2003. EBNA1 partitions Epstein-Barr virus plasmids in yeast cells by attaching to human EBNA1-binding protein 2 on mitotic chromosomes. J. Virol. 77:6946-6956.
7. Kapoor P, Shire K, Frappier L. 2001. Reconstitution of Epstein-Barr virus-based plasmid partitioning in budding yeast. EMBO J. 20:222-230.
8. Shire K, Ceccarelli DF, Avolio-Hunter TM, Frappier L. 1999. EBP2, a human protein that interacts with sequences of the Epstein-Barr virus nuclear antigen 1 important for plasmid maintenance. J. Virol. 73:2587-2595.
9. Wu H, Ceccarelli DF, Frappier L. 2000. The DNA segregation mechanism of EpsteinBarr virus nuclear antigen 1. EMBO Rep. 1:140-144.
10. Krithivas A, Fujimuro M, Weidner M, Young DB, Hayward SD. 2002. Protein interactions targeting the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes. J. Virol. 76:11596-11604.
11. Barbera AJ, Chodaparambil JV, Kelley-Clarke B, Luger K, Kaye KM. 2006. Kaposi's sarcoma-associated herpesvirus LANA hitches a ride on the chromosome. Cell Cycle 5:1048-1052.
12. Barbera AJ, Chodaparambil JV, Kelley-Clarke B, Joukov V, Walter JC, Luger K, Kaye KM. 2006. The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA. Science 311:856-861.
13. Cotter MA, 2nd, Robertson ES. 1999. The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavitybased lymphoma cells. Virology 264:254-264.
14. Paulus C, Nevels M. 2009. The human cytomegalovirus major immediate-early proteins as antagonists of intrinsic and innate antiviral host reponses. Viruses 1:760-779.
15. Meier JL, Stinski MF. 2013. Major immediate-early enhancer and its gene products, p 152-173. In Reddehase MJ (ed), Cytomegaloviruses: from molecular pathogenesis to intervention, 2nd ed, vol 1. Caister Academic Press, Norfolk, United Kingdom.
16. Mocarski ES, Shenk T, Pass RF. 2007. Cytomegaloviruses, p 2701-2772. In Knipe DM, Howley PM (ed), Fields virology, 5th ed, vol 2. Lippincott Williams \& Wilkins, Philadelphia, PA.
17. Mocarski ES, Kemble GW, Lyle JM, Greaves RF. 1996. A deletion mutant in the human cytomegalovirus gene encoding IE1(491aa) is replication defective due to a failure in autoregulation. Proc. Natl. Acad. Sci. U. S. A. 93:11321-11326.
18. Greaves RF, Mocarski ES. 1998. Defective growth correlates with reduced accumulation of a viral DNA replication protein after low-multiplicity infection by a human cytomegalovirus ie1 mutant. J. Virol. 72:366-379.
19. Gawn JM, Greaves RF. 2002. Absence of IE1 p72 protein function during lowmultiplicity infection by human cytomegalovirus results in a broad block to viral delayedearly gene expression. J. Virol. 76:4441-4455.
20. Lafemina RL, Pizzorno MC, Mosca JD, Hayward GS. 1989. Expression of the acidic nuclear immediate-early protein (IE1) of human cytomegalovirus in stable cell lines and its preferential association with metaphase chromosomes. Virology 172:584-600.
21. Krauss S, Kaps J, Czech N, Paulus C, Nevels M. 2009. Physical requirements and functional consequences of complex formation between the cytomegalovirus IE1 protein and human STAT2. J. Virol. 83:12854-12870.
22. Reinhardt J, Smith GB, Himmelheber CT, Azizkhan-Clifford J, Mocarski ES. 2005. The carboxyl-terminal region of human cytomegalovirus IE1491aa contains an acidic domain that plays a regulatory role and a chromatin-tethering domain that is dispensable during viral replication. J. Virol. 79:225-233.
23. Shin HJ, Kim YE, Kim ET, Ahn JH. 2012. The chromatin-tethering domain of human cytomegalovirus immediate-early (IE) 1 mediates associations of IE1, PML and STAT2
with mitotic chromosomes, but is not essential for viral replication. J. Gen. Virol. 93:716721.
24. Wilkinson GW, Kelly C, Sinclair JH, Rickards C. 1998. Disruption of PML-associated nuclear bodies mediated by the human cytomegalovirus major immediate early gene product. J. Gen. Virol. 79:1233-1245.
25. Dimitropoulou P, Caswell R, McSharry BP, Greaves RF, Spandidos DA, Wilkinson GW, Sourvinos G. 2010. Differential relocation and stability of PML-body components during productive human cytomegalovirus infection: Detailed characterization by live-cell imaging. Eur. J. Cell Biol. 89:757-768.
26. Ahn JH, Brignole EJ, 3rd, Hayward GS. 1998. Disruption of PML subnuclear domains by the acidic IE1 protein of human cytomegalovirus is mediated through interaction with PML and may modulate a RING finger-dependent cryptic transactivator function of PML. Mol. Cell. Biol. 18:4899-4913.
27. Huh YH, Kim YE, Kim ET, Park JJ, Song MJ, Zhu H, Hayward GS, Ahn JH. 2008. Binding STAT2 by the acidic domain of human cytomegalovirus IE1 promotes viral growth and is negatively regulated by SUMO. J. Virol. 82:10444-10454.
28. Nevels M, Brune W, Shenk T. 2003. SUMOylation of the human cytomegalovirus major immediate-early protein IE1-72kDa contributes to efficient viral replication by promoting the accumulation of IE2-86kDa. J. Virol. 78:7803-7812.
29. Chang YN, Jeang KT, Lietman T, Hayward GS. 1995. Structural organization of the spliced immediate-early gene complex that encodes the major acidic nuclear (IE1) and transactivator (IE2) proteins of African green monkey cytomegalovirus. J. Biomed. Sci. 2:105-130.
30. Tanaka M, Herr W. 1990. Differential transcriptional activation by Oct-1 and Oct-2: interdependent activation domains induce Oct-2 phosphorylation. Cell 60:375-386.
31. Maruyama K, Takebe Y. 1990. New trend of cDNA cloning. Med. Immunol. (Tokyo) 20:27-32.
32. Guan KL, Dixon JE. 1991. Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. Anal. Biochem. 192:262-267.
33. Tatham MH, Jaffray E, Vaughan OA, Desterro JM, Botting CH, Naismith JH, Hay RT. 2001. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J. Biol. Chem. 276:35368-35374.
34. Baldick CJ, Jr., Marchini A, Patterson CE, Shenk T. 1997. Human cytomegalovirus tegument protein pp71 (ppUL82) enhances the infectivity of viral DNA and accelerates the infectious cycle. J. Virol. 71:4400-4408.
35. Shiio Y, Eisenman RN. 2003. Histone sumoylation is associated with transcriptional repression. Proc. Natl. Acad. Sci. U. S. A. 100:13225-13230.
36. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51-59.
37. Jacobs JP, Jones CM, Baille JP. 1970. Characteristics of a human diploid cell designated MRC-5. Nature 227:168-170.
38. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD, et al. 1992. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171-180.
39. Plotkin SA, Furukawa T, Zygraich N, Huygelen C. 1975. Candidate cytomegalovirus strain for human vaccination. Infect. Immun. 12:521-527.
40. Knoblach T, Grandel B, Seiler J, Nevels M, Paulus C. 2011. Human cytomegalovirus IE1 protein elicits a type II interferon-like host cell response that depends on activated STAT1 but not interferon- $\gamma$. PLoS Pathog 7:e1002016.
41. Marchini A, Liu H, Zhu H. 2001. Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes. J. Virol. 75:1870-1878.
42. Riegler S, Hebart H, Einsele H, Brossart P, Jahn G, Sinzger C. 2000. Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. J. Gen. Virol. 81:393-399.
43. Sinzger C, Hahn G, Digel M, Katona R, Sampaio KL, Messerle M, Hengel H, Koszinowski U, Brune W, Adler B. 2008. Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J. Gen. Virol. 89:359-368.
44. Tischer BK, Smith GA, Osterrieder N. 2010. En passant mutagenesis: a two step markerless red recombination system. Methods Mol. Biol. 634:421-430.
45. Tischer BK, von Einem J, Kaufer B, Osterrieder N. 2006. Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40:191-197.
46. Gerna G, Percivalle E, Sarasini A, Baldanti F, Revello MG. 2002. The attenuated Towne strain of human cytomegalovirus may revert to both endothelial cell tropism and leuko- (neutrophil- and monocyte-) tropism in vitro. J. Gen. Virol. 83:1993-2000.
47. Hahn G, Khan H, Baldanti F, Koszinowski UH, Revello MG, Gerna G. 2002. The human cytomegalovirus ribonucleotide reductase homolog UL45 is dispensable for growth in endothelial cells, as determined by a BAC-cloned clinical isolate of human cytomegalovirus with preserved wild-type characteristics. J. Virol. 76:9551-9555.
48. Smith GA, Enquist LW. 1999. Construction and transposon mutagenesis in Escherichia coli of a full-length infectious clone of pseudorabies virus, an alphaherpesvirus. J. Virol. 73:6405-6414.
49. Yu D, Smith GA, Enquist LW, Shenk T. 2002. Construction of a self-excisable bacterial artificial chromosome containing the human cytomegalovirus genome and mutagenesis of the diploid TRL/IRL13 gene. J. Virol. 76:2316-2328.
50. Rodriguez-Collazo P, Leuba SH, Zlatanova J. 2009. Robust methods for purification of histones from cultured mammalian cells with the preservation of their native modifications. Nucleic Acids Res. 37:e81.
51. Nevels M, Paulus C, Shenk T. 2004. Human cytomegalovirus immediate-early 1 protein facilitates viral replication by antagonizing histone deacetylation. Proc. Natl. Acad. Sci. U. S. A. 101:17234-17239.
52. Zhu H, Shen Y, Shenk T. 1995. Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J. Virol. 69:7960-7970.
53. Graham FL, van der Eb AJ. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-467.
54. Möglich A, Weinfurtner D, Gronwald W, Maurer T, Kalbitzer HR. 2005. PERMOL: restraint-based protein homology modeling using DYANA or CNS. Bioinformatics 21:2110-2111.
55. Gronwald W, Brunner K, Kirchhöfer R, Nasser A, Trenner J, Ganslmeier B, Riepl H, Ried A, Scheiber J, Elsner R, Neidig KP, Kalbitzer HR. 2004. AUREMOL, a new program for the automated structure elucidation of biological macromolecules. Bruker Rep. 154/155:11-14.
56. Brunger AT. 2007. Version 1.2 of the Crystallography and NMR system. Nat. Protoc. 2:2728-2733.
57. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL. 1998. Crystallography \& NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54:905-921.
58. Linge JP, Williams MA, Spronk CA, Bonvin AM, Nilges M. 2003. Refinement of protein structures in explicit solvent. Proteins 50:496-506.
59. Piolot T, Tramier M, Coppey M, Nicolas JC, Marechal V. 2001. Close but distinct regions of human herpesvirus 8 latency-associated nuclear antigen 1 are responsible for nuclear targeting and binding to human mitotic chromosomes. J. Virol. 75:3948-3959.
60. Shinohara H, Fukushi M, Higuchi M, Oie M, Hoshi O, Ushiki T, Hayashi J, Fujii M. 2002. Chromosome binding site of latency-associated nuclear antigen of Kaposi's sarcomaassociated herpesvirus is essential for persistent episome maintenance and is functionally replaced by histone H1. J. Virol. 76:12917-12924.
61. Roussel L, Erard M, Cayrol C, Girard JP. 2008. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep. 9:1006-1012.
62. Möglich A, Weinfurtner D, Maurer T, Gronwald W, Kalbitzer HR. 2005. A restraint molecular dynamics and simulated annealing approach for protein homology modeling utilizing mean angles. BMC Bioinformatics 6:91.
63. Kalashnikova AA, Porter-Goff ME, Muthurajan UM, Luger K, Hansen JC. 2013. The role of the nucleosome acidic patch in modulating higher order chromatin structure. J. R. Soc. Interface 10:20121022.
64. Bönisch C, Hake SB. 2012. Histone H2A variants in nucleosomes and chromatin: more or less stable? Nucleic Acids Res. 40:10719-10741.
65. Makde RD, England JR, Yennawar HP, Tan S. 2010. Structure of RCC1 chromatin factor bound to the nucleosome core particle. Nature 467:562-566.
66. Kato H, van Ingen H, Zhou BR, Feng H, Bustin M, Kay LE, Bai Y. 2011. Architecture of the high mobility group nucleosomal protein 2 -nucleosome complex as revealed by methyl-based NMR. Proc. Natl. Acad. Sci. U. S. A. 108:12283-12288.
67. Armache KJ, Garlick JD, Canzio D, Narlikar GJ, Kingston RE. 2011. Structural basis of silencing: Sir3 BAH domain in complex with a nucleosome at $3.0 \AA$ resolution. Science 334:977-982.
68. Matsumoto Y, Hayashi Y, Omori H, Honda T, Daito T, Horie M, Ikuta K, Fujino K, Nakamura S, Schneider U, Chase G, Yoshimori T, Schwemmle M, Tomonaga K. 2012. Bornavirus closely associates and segregates with host chromosomes to ensure persistent intranuclear infection. Cell Host Microbe 11:492-503.
69. Tobaly-Tapiero J, Bittoun P, Lehmann-Che J, Delelis O, Giron ML, de The H, Saib A. 2008. Chromatin tethering of incoming foamy virus by the structural Gag protein. Traffic 9:1717-1727.
70. Terhune SS, Moorman NJ, Cristea IM, Savaryn JP, Cuevas-Bennett C, Rout MP, Chait BT, Shenk T. 2010. Human cytomegalovirus UL29/28 protein interacts with components of the NuRD complex which promote accumulation of immediate-early RNA. PLoS Pathog. 6: 1000965.
71. Saffert RT, Kalejta RF. 2006. Inactivating a cellular intrinsic immune defense mediated by Daxx is the mechanism through which the human cytomegalovirus pp71 protein stimulates viral immediate-early gene expression. J. Virol. 80:3863-3871.
72. Penkert RR, Kalejta RF. 2011. Tegument protein control of latent herpesvirus establishment and animation. Herpesviridae 2:3.
73. Nevels M, Nitzsche A, Paulus C. 2011. How to control an infectious bead string: nucleosome-based regulation and targeting of herpesvirus chromatin. Rev Med Virol. 21:154-180.
74. Paulus C, Nitzsche A, Nevels M. 2010. Chromatinisation of herpesvirus genomes. Rev Med Virol 20:34-50.
75. Knipe DM, Lieberman PM, Jung JU, McBride AA, Morris KV, Ott M, Margolis D, Nieto A, Nevels M, Parks RJ, Kristie TM. 2012. Snapshots: chromatin control of viral infection. Virology 435:141-156.
76. Reeves M, Sinclair J. 2013. Regulation of human cytomegalovirus transcription in latency: beyond the major immediate-early promoter. Viruses 5:1395-1413.
77. Arlt H, Lang D, Gebert S, Stamminger T. 1994. Identification of binding sites for the 86kilodalton IE2 protein of human cytomegalovirus within an IE2-responsive viral early promoter. J. Virol. 68:4117-4125.
78. Macias MP, Stinski MF. 1993. An in vitro system for human cytomegalovirus immediate early 2 protein (IE2)-mediated site-dependent repression of transcription and direct binding of IE2 to the major immediate early promoter. Proc. Natl. Acad. Sci. U. S. A. 90:707-711.
79. Waheed I, Chiou CJ, Ahn JH, Hayward GS. 1998. Binding of the human cytomegalovirus $80-\mathrm{kDa}$ immediate-early protein (IE2) to minor groove $\mathrm{A} / \mathrm{T}-\mathrm{rich}$ sequences bounded by CG dinucleotides is regulated by protein oligomerization and phosphorylation. Virology 252:235-257.
80. Ahn JH, Chiou CJ, Hayward GS. 1998. Evaluation and mapping of the DNA binding and oligomerization domains of the IE2 regulatory protein of human cytomegalovirus using yeast one and two hybrid interaction assays. Gene 210:25-36.
81. Lee SB, Lee CF, Ou DS, Dulal K, Chang LH, Ma CH, Huang CF, Zhu H, Lin YS, Juan LJ. 2011. Host-viral effects of chromatin assembly factor 1 interaction with HCMV IE2. Cell Res. 21:1230-1247.
82. Park JJ, Kim YE, Pham HT, Kim ET, Chung YH, Ahn JH. 2007. Functional interaction of the human cytomegalovirus IE2 protein with histone deacetylase 2 in infected human fibroblasts. J. Gen. Virol. 88:3214-3223.
83. Reeves M, Murphy J, Greaves R, Fairley J, Brehm A, Sinclair J. 2006. Autorepression of the human cytomegalovirus major immediate-early promoter/enhancer at late times of infection is mediated by the recruitment of chromatin remodeling enzymes by IE86. J. Virol. 80:9998-10009.
84. Maul GG, Negorev D. 2008. Differences between mouse and human cytomegalovirus interactions with their respective hosts at immediate early times of the replication cycle. Med. Microbiol. Immunol. 197:241-249.
85. Münch K, Keil GM, Messerle M, Koszinowski UH. 1988. Interaction of the 89 K murine cytomegalovirus immediate-early protein with core histones. Virology 163:405-412.
86. Münch K, Messerle M, Plachter B, Koszinowski UH. 1992. An acidic region of the 89 K murine cytomegalovirus immediate early protein interacts with DNA. J. Gen. Virol. 73:499-506.
87. Nitzsche A, Paulus C, Nevels M. 2008. Temporal dynamics of cytomegalovirus chromatin assembly in productively infected human cells. J. Virol. 82:11167-11180.
88. Zalckvar E, Paulus C, Tillo D, Asbach-Nitzsche A, Lubling Y, Winterling C, Strieder N, Mucke K, Goodrum F, Segal E, Nevels M. 2013. Nucleosome maps of the human cytomegalovirus genome reveal a temporal switch in chromatin organization linked to a major IE protein. Proc. Natl. Acad. Sci. U. S. A. 110:13126-13131.
89. Nitzsche A, Steinhäußer C, Mücke K, Paulus C, Nevels M. 2012. Histone H3 lysine 4 methylation marks postreplicative human cytomegalovirus chromatin. J. Virol. 6:98179827.
90. Dorigo B, Schalch T, Bystricky K, Richmond TJ. 2003. Chromatin fiber folding: requirement for the histone H 4 N-terminal tail. J. Mol. Biol. 327:85-96.
91. Kan PY, Caterino TL, Hayes JJ. 2009. The H4 tail domain participates in intra- and internucleosome interactions with protein and DNA during folding and oligomerization of nucleosome arrays. Mol. Cell. Biol. 29:538-546.
92. Chodaparambil JV, Barbera AJ, Lu X, Kaye KM, Hansen JC, Luger K. 2007. A charged and contoured surface on the nucleosome regulates chromatin compaction. Nat. Struct. Mol. Biol. 14:1105-1107.
93. Stuber G, Mattsson K, Flaberg E, Kati E, Markasz L, Sheldon JA, Klein G, Schulz TF, Szekely L. 2007. HHV-8 encoded LANA-1 alters the higher organization of the cell nucleus. Mol. Cancer 6:28.
94. Ballestas ME, Chatis PA, Kaye KM. 1999. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284:641-644.
95. Ohsaki E, Ueda K. 2012. Kaposi's sarcoma-associated herpesvirus genome replication, partitioning, and maintenance in latency. Front. Microbiol. 3:1-12.
96. Feeney KM, Parish JL. 2009. Targeting mitotic chromosomes: a conserved mechanism to ensure viral genome persistence. Proc. Biol. Sci. 276:1535-1544.
97. DeLano WL. 2002. The PyMOL user's manual. DeLano Scientific, San Carlos, CA.
98. Benson DA, Karsch-Mizrachi I, Clark K, Lipman DJ, Ostell J, Sayers EW. 2012. GenBank. Nucleic Acids Res. 40:D48-53.
99. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ. 2009. Jalview Version 2--a multiple sequence alignment editor and analysis workbench. Bioinformatics 25:11891191.
100. Crooks GE, Hon G, Chandonia JM, Brenner SE. 2004. WebLogo: a sequence logo generator. Genome Res. 14:1188-1190.

## Figure Legends

FIG 1 hCMV IE1 interacts with human nucleosomes and all four core histones in a nucleic acidindependent fashion.
(A) Results of co-immunoprecipitations from plasmid-transfected cells. H1299 cells were transfected with plasmids encoding the indicated HA-tagged viral proteins or with empty vector (w/o). Cell extracts were combined with nucleosomes derived from MNase-digested human cell nuclei. Samples were subjected to immunoprecipitation using anti-HA or anti-Flag agarose. Input and output protein samples were separated in 10 or $15 \%$ polyacrylamide-SDS gels, and HAtagged proteins and individual core histones were detected by immunoblotting. See also Fig. S1.
(B) Results of co-immunoprecipitations from hCMV-infected cells. Following infection of MRC5 cells with TNwt or TNdIIE1 viruses ( $3 \mathrm{PFU} /$ cell for 72 h ), cells were fixed with formaldehyde, and cell extracts were sonicated to solubilize nucleosomes. Samples were subjected to immunoprecipitation using rabbit antibodies to histone H 3 or non-specific rabbit $\operatorname{IgG}$ (rbIgG). Input and output protein samples were separated in 15\% polyacrylamide-SDS gels, and the IE1 protein and histone H 3 were detected by immunoblotting.
(C) Results of in vitro GST pull-down assays. Equal volumes of empty glutathione sepharose beads or beads carrying GST or GST-IE1 were reacted with acid-extracted human histones in the absence or presence of DNase I and RNase A. Input (8\% of output) and output protein samples were separated in $15 \%$ polyacrylamide-SDS gels and stained with Coomassie Brilliant Blue.

FIG 2 hCMV IE1 exhibits two separable histone binding domains with differential specificities for H2A-H2B and H3-H4.
(A) Schematic of wild-type and mutant hCMV IE1 and KSHV LANA proteins with relative locations of their CTDs.
(B) Results of in vitro GST pull-down assays with acid-extracted unfractionated human histones. Empty glutathione sepharose beads or beads carrying GST or the indicated GST fusion proteins were reacted with acid-extracted human histones. Input and output protein samples were separated along with purified recombinant human core histones ( $\mathrm{H} 2 \mathrm{~A}, \mathrm{H} 2 \mathrm{~B}, \mathrm{H} 3$, and H 4 from New England Biolabs) in a $15 \%$ polyacrylamide-SDS gel and stained with Coomassie Brilliant Blue. The asterisk marks H1 histones.
(C) Results of in vitro GST pull-down assays with acid-extracted human histones separated into H2A-H2B and H3-H4 fractions. Equal volumes of empty glutathione sepharose beads or beads carrying GST or the indicated GST fusion proteins were reacted with purified human $\mathrm{H} 2 \mathrm{~A}-\mathrm{H} 2 \mathrm{~B}$ or $\mathrm{H} 3-\mathrm{H} 4$. Input ( $8 \%$ of output) and output protein samples were separated in $15 \%$ polyacrylamide-SDS gels and stained with Coomassie Brilliant Blue.

FIG 3 Alanine scanning mutagenesis identifies IE1 CTD residues critical for histone binding.
(A) Presentation of wild-type (wt) and mutant IE1 $1_{476-491}$ protein sequences. Amino acids substituted by alanine scanning mutagenesis are highlighted.
(B) Results of in vitro GST pull-down assays. Glutathione sepharose beads carrying GST or the indicated wild-type (wt) and mutant GST-IE1 ${ }_{476-491}$ fusion proteins (see also Fig. 3A) were reacted with acid-extracted histones. Input ( $14 \%$ of output) and output protein samples were separated in 15\% polyacrylamide-SDS gels and stained with Coomassie Brilliant Blue.
(C) Quantitative assessment of GST pull-down assay results. The output bands were quantified by densitometry, and bars represent the ratio of histones H3, H2B, H2A, and H4 to GST-IE1476-
491. Results for the CTD mutants are presented relative to the CTD wt sample present on the same gel (set to $100 \%$ ).

FIG 4 Alanine scanning mutagenesis identifies IE1 CTD residues critical for mitotic chromatin association.
(A) Results of co-localization analyses in mitotic cells. H1299 cells were transfected with plasmids encoding EGFP or the indicated wild-type (wt) and mutant EGFP-IE1 ${ }_{476-491}$ fusion proteins (see also Fig. 3A). Cells were fixed with methanol, immunostained for EGFP, and counterstained for DNA with DAPI. Representative individual and merged images of EGFP and DAPI signals are presented.
(B) Quantitative assessment of co-localization analysis results. The extent of overlap between pixels in the green and blue channels was quantified by calculating Pearson's correlation coefficients $(1=$ perfect positive correlation, $0=$ no correlation, $-1=$ perfect negative correlation). Bars represent means from at least three randomly selected mitotic cell images with standard deviations. A Student's t-test was performed to check for statistical significance of differences between CTD wt and the respective mutant ( ${ }^{*} p<0.1,{ }^{* *} p<0.01$ ).
(C) Assessment of essential CTD residues in the background of full-length IE1. H1299 cells were transfected with pCMV.TetO-derived plasmids encoding wild-type IE1, IE1 $1_{1-475}$, or full-length IE1 with alanine substitutions of all four (IE1 NBM) or one single (IE1 M483A) CTD residue determined to be essential in (A) and (B). Cells were fixed with methanol, immunostained for IE1, and counterstained for DNA with DAPI. Representative individual and merged images of IE1 and DAPI signals are presented.
(D) Delineation of the nucleosome binding motif (NBM) within the IE1 CTD as deduced from data shown in (A), (B), (C), and Fig. 3. Amino acids determined to be essential or accessory for histone binding and chromatin association are highlighted.

FIG 5 Site-directed mutagenesis identifies human H2A residues critical for interaction with IE1. (A) H2A residues targeted by mutagenesis and evaluated for contributions to IE1 binding. The complete sequence of human histone H2A. 2 (H2A type 1-B/E) is shown, with acidic residues in bold letters and amino acids forming the acidic pocket underlined.
(B) Results of in vitro GST pull-down assays performed with the IE1 CTD. Empty glutathione sepharose beads or beads carrying GST-IE1 ${ }_{476-491}$ were reacted with acid-extracted human histones from H1299 cells transfected with empty vector (w/o) or plasmids encoding the indicated Flag-tagged H2A proteins. Input and output protein samples were separated in $15 \%$ polyacrylamide-SDS gels and stained with Coomassie Brilliant Blue. Flag-H2A proteins were detected by immunoblotting.
(C) Results of co-immunoprecipitations performed with full-length IE1 protein. H1299 cells were simultaneously transfected with empty vector (w/o) or plasmids encoding the indicated wild-type (wt) and mutant Flag-H2A proteins and plasmids encoding either HA-tagged full-length IE1 or HA-IE1 $1_{1-475}$. Cells were fixed with formaldehyde, and cell extracts were sonicated to solubilize nucleosomes. Samples were subjected to immunoprecipitation using anti-HA or mouse $\operatorname{IgG}$ ( mIgG ) agarose. Input and output protein samples were separated in 10 or $15 \%$ polyacrylamideSDS gels, and Flag- and HA-tagged proteins were detected by immunoblotting.
(D) Quantitative assessment of results. The $\alpha$-Flag bands shown in (C) were quantified by densitometry, and bars represent the ratio of output to input signal intensities relative to the H 2 A wt sample present on the same blot (set to $100 \%$ ).

FIG 6 The IE1 and LANA CTDs compete for binding to human core histones.
(A) Full-length IE1 competes with GST-LANA ${ }_{5-22}$ for histone binding.
(B) IE1 lacking the CTD $\left(\mathrm{IE1}_{1-475}\right)$ is less active in competing with GST-LANA ${ }_{5-22}$ for histone binding compared to the full-length protein.
(C) A peptide encompassing LANA $_{5-22}$ (LANA-CTD), but not a mutant peptide (LANA-CTD*), interferes with histone binding to GST-IE1 $1_{476-491}$.

Acid-extracted human histones were combined with solvent or with the indicated soluble IE1 proteins (A, B) or LANA peptides (C) and then subjected to in vitro GST pull-down assays with glutathione sepharose beads carrying GST-LANA ${ }_{5-22}(A, B)$ or GST-IE1 ${ }_{476-491}$ (C). Input and output protein samples were separated in $15 \%$ polyacrylamide-SDS gels and stained with Coomassie Brilliant Blue. See also Fig. S3.

FIG 7 The IE1 CTD is predicted to adopt a $\beta$-hairpin structure that docks with the acidic pocket formed by H2A-H2B on the nucleosomal surface.
(A) Amino acid sequence alignment of $\mathrm{IE1}_{476-491}$ and $\mathrm{LANA}_{4-17}(*=$ identical residue, $:=$ conserved substitution,.$=$ semi-conserved substitution) used for homology modeling.
(B) Bundles of the ten lowest total energy structures for IE1 ${ }_{476-491}$ after explicit water refinement $($ RMSD $=0.038 \mathrm{~nm})$ based on the sequence alignment of $(\mathrm{A})$ and the $\mathrm{LANA}_{4-17}$-nucleosome crystal structure (PDB: 1zla).
(C) Predicted intra- and intermolecular hydrogen bonds in the IE1 ${ }_{476-491}$-nucleosome complex based on the sequence alignment of (A) and the LANA $_{4-17}$-nucleosome crystal structure (PDB: 1zla). Black arrows symbolize predicted interactions between IE1 CTD and H 2 A or H 2 B residues also observed in the LANA-nucleosome complex, and red arrows represent predicted interactions unique to the IE1-nucleosome complex. Arrow tails define the donor and arrow heads point at the acceptor of a possible hydrogen bond.
(D) Front view of detailed total best energy homology model of the molecular interaction between $\mathrm{IE1}_{476-491}$ and the H2A-H2B dimer based on the sequence alignment of (A) and the LANA $_{4-17}$-nucleosome crystal structure after explicit water refinement. The model is presented as displayed in PyMOL (http://www.pymol.org) (97) showing the H2A-H2B dimer in surface representation. Blue color represents positively charged and red color negatively charged side chains. The H2A residues predicted or experimentally determined to be critical for binding to IE1 ${ }_{476-491}$ (see Fig. 5) are indicated. The IE1 ${ }_{476-491}$ peptide is shown in a ball-and-stick representation. IE1 residues P482 and R486 are marked by arrows for better orientation.
(E) Model (D) after $90^{\circ}$ turn in indicated direction. See also Fig. S4 and Movie S1.

FIG 8 Steady-state levels and chromatin association of wild-type and mutant IE1 proteins in hCMV-infected cells.
(A) IE1 and IE2 steady-state protein levels in hCMV TB40E infections. MRC-5 cells were mockinfected or infected with TBwt, $\mathrm{TBrvIE}_{1-475}$, or $\mathrm{TBIE}_{1-475}$ at $3 \mathrm{PFU} /$ cell, and viral IE1/IE2 protein levels were monitored over time by separation in $10 \%$ polyacrylamide-SDS gels and immunoblotting. Detection of the cellular GAPDH protein served as a loading control.
(B) IE1 and IE2 steady-state protein levels in hCMV FIX infections. MRC-5 cells were mockinfected or infected with FXwt, FXrvIE1, or FXIE1 $1_{1-475}$ at 3 PFU/cell, and viral IE1/IE2 protein
levels were monitored over time by separation in $10 \%$ polyacrylamide-SDS gels and immunoblotting. Detection of the cellular GAPDH protein served as a loading control.
(C) Mitotic chromatin association of IE1 in hCMV TB40E infections. MRC-5 cells were mockinfected or infected with TBwt, TBrvIE1 $1_{1-475}$, or TBIE $_{1-475}$ at 3 PFU/cell for 48 h , and the localization of the viral IE1 protein relative to cellular mitotic chromatin (stained with DAPI) was detected by indirect immunofluorescence using a 1:1 mix of antibodies IE1.G10 and 6E1.
(D) Mitotic chromatin association of IE1 in hCMV FIX infections. MRC-5 cells were mockinfected or infected with FXwt, FXrvIE1, or FXIE1 $1_{1-475}$ at 3 PFU/cell for 48 h , and the localization of the viral IE1 protein relative to cellular mitotic chromatin (stained with DAPI) was detected by indirect immunofluorescence using antibody IE1.G10.

FIG 9 The IE1 CTD is not required for efficient hCMV productive infection.
(A) Single-step replication analysis of TB40E viruses. MRC-5 cells were infected with TBwt, TBrvIE1 $1_{1-475}$, or TBIE1 $1_{1-475}$ (two independent clones) at high input multiplicity (3 PFU/cell), and extracellular viral genomes were monitored over time by qPCR-based relative quantification. Data represent means and standard deviations from duplicate infections each measured twice (TBwt at 0 days post infection set to 1 ).
(B) Peak virus titers in high multiplicity TB40E infections. Extracellular infectious particles from 7 days post infection (A) were quantified by standard plaque assay on MRC-5 cells. Data represent means and standard deviations from duplicate infections each measured twice. (C) Multi-step replication analysis of TB40E viruses. MRC-5 cells were infected with TBwt, TBrvIE1 $_{1-475}$, or TBIE1 $1_{1-475}$ (two independent clones) at low input multiplicity ( $0.03 \mathrm{PFU} /$ cell), and extracellular viral genomes were monitored over time by qPCR-based relative quantification.

Data represent means and standard deviations from duplicate infections each measured twice (TBwt at 0 days post infection set to 1 ).
(D) Peak virus titers in low multiplicity TB40E infections. Extracellular infectious particles from 16 days post infection (C) were quantified by standard plaque assay on MRC-5 cells. Data represent means and standard deviations from duplicate experiments each measured twice. (E) Single-step replication analysis of FIX viruses. MRC-5 cells were infected with FXwt, FXrvIE1, or FXIE1 $1_{1-475}$ (two independent clones) at high input multiplicity ( $3 \mathrm{PFU} /$ cell), and extracellular viral genomes were monitored over time by qPCR-based relative quantification. Data represent means and standard deviations from duplicate infections each measured twice (FXwt at 0 days post infection set to 1 ).
(F) Peak virus titers in high multiplicity FIX infections. Extracellular infectious particles from 6 days post infection (E) were quantified by standard plaque assay on MRC-5 cells. Data represent means and standard deviations from duplicate infections each measured twice.
(G) Multi-step replication analysis of FIX viruses. MRC-5 cells were infected with FXwt, FXrvIE1, or FXIE1 $1_{1-475}$ (two independent clones) at low input multiplicity ( $0.05 \mathrm{PFU} / \mathrm{cell}$ ), and extracellular viral genomes were monitored over time by qPCR-based relative quantification. Data represent means and standard deviations from duplicate infections each measured twice (FXwt at 0 days post infection set to 1 ).
(H) Peak virus titers in low multiplicity FIX infections. Extracellular infectious particles from 15 days post infection (G) were quantified by standard plaque assay on MRC-5 cells. Data represent means and standard deviations from duplicate infections each measured twice.

FIG 10 The IE1 NBM is selectively conserved through primate CMV evolution.
(A) Alignment of orthologous IE1 sequences from hCMV (Towne) and all non-human primate CMV isolates present in GenBank (National Center for Biotechnology Information) (98) including chimpanzee CMV (panine herpesvirus 2), african green monkey (simian) CMV (cercopithecine herpesvirus 5), rhesus macaque CMV (Macaca mulatta CMV and Macacine herpesvirus 3, 68-1 strain), and baboon CMV. The multiple sequence alignment was generated using ClustalW2 (European Bioinformatics Institute; http://www.ebi.ac.uk/tools/msa/clustalw2) with default settings and rendered using Jalview 2.7 (http://www.jalview.org) (99). The extent of amino acid conservation is visualized by shades of blue. CTD and NBM sequences are marked. (B) Table presenting GenBank accession numbers of orthologous IE1 sequences from primate CMVs and \% amino acid sequence identities of full-length IE1 proteins, IE1 CTDs, and IE1 NBMs relative to the corresponding hCMV IE1 (Towne) sequence based on pairwise alignments (IE1) or the multiple sequence alignment shown in (A) (CTD, NBM).
(C) Sequence logo illustrating extent of amino acid conservation in orthologous IE1 CTD sequences from primate CMVs. The sequence logo was generated using WebLogo 2.8.2 (http://weblogo.berkeley.edu) (100) with default color code. Amino acids are numbered according to their positions in the hCMV (Towne) IE1 sequence. Numbers corresponding to amino acids forming the hCMV IE1 NBM are printed in bold type, and residues essential for nucleosome and chromosome interaction are underlined.

B $\qquad$ output




Figure 3

| CTD wt | G | G | K | S | T | H | P | M | V | T | R | S | K | A | D | Q |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| G476A | A | G | K | S | T | H | P | M | V | T | R | S | K | A | D | Q |
| G477A | G | A | K | S | T | H | P | M | V | T | R | S | K | A | D | Q |
| K478A | G | G | A | S | T | H | P | M | V | T | R | S | K | A | D | Q |
| S479A | G | G | K | A | T | H | P | M | V | T | R | S | K | A | D | Q |
| T480A | G | G | K | S | A | H | P | M | V | T | R | S | K | A | D | Q |
| H481A | G | G | K | S | T | A | P | M | V | T | R | S | K | A | D | Q |
| P482A | G | G | K | S | T | H | A | M | V | T | R | S | K | A | D | Q |
| M483A | G | G | K | S | T | H | P | A | V | T | R | S | K | A | D | Q |
| V484A | G | G | K | S | T | H | P | M | A | T | R | S | K | A | D | Q |
| T485A | G | G | K | S | T | H | P | M | V | A | R | S | K | A | D | Q |
| R486A | G | G | K | S | T | H | P | M | V | T | A | S | K | A | D | Q |
| S487A | G | G | K | S | T | H | P | M | V | T | R | A | K | A | D | Q |
| K488A | G | G | K | S | T | H | P | M | V | T | R | S | A | A | D | Q |
| A489G | G | G | K | S | T | H | P | M | V | T | R | S | K | G | D | Q |
| D490A | G | G | K | S | T | H | P | M | V | T | R | S | K | A | A | Q |
| Q491A | G | G | K | S | T | H | P | M | V | T | R | S | K | A | D | A |





C


D IE1 NBM
$\begin{array}{ccccccccccccccccc}\text { G } & \text { G } & \text { K } & \text { S } & \text { T } & \text { H } & \text { P } & \text { M } & \text { V } & \text { T } & \text { R } & \text { S } & \text { K } & \text { A } & \text { D } & \text { Q }\end{array}$
46477478479480481482483484485486487488489490491essential


Figure 6


$\stackrel{\rightharpoonup}{2}$


## A

| LANA | 4 | PGMRLR--SGRSTGAP | 17 |
| :--- | :--- | :--- | ---: |
| IE1 | 476 | GGKSTHPMVTRSKADQ | 491 |

B


Figure 8

| A |  |  |  | mock |  |  |  | TBwt |  |  |  | TBrvIE1 ${ }_{1-475}$ |  |  |  | TBwt |  |  |  | TBIE1 $1_{1-475}$ |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| ¢ | $\stackrel{ᄃ}{\underset{\sim}{\sim}}$ | $\stackrel{ᄃ}{\infty}$ | $\frac{ᄃ}{\varrho}$ | $\frac{ᄃ}{6}$ | $\stackrel{ᄃ}{\underset{\sim}{\sim}}$ | $\stackrel{\subset}{\infty}$ | $\frac{ᄃ}{\varrho}$ | $\frac{\square}{0}$ | $\stackrel{ᄃ}{\underset{\sim}{\sim}}$ | $\stackrel{ᄃ}{\infty}$ | $\stackrel{ᄃ}{6}$ | $\frac{ᄃ}{\bullet}$ | $\stackrel{ᄃ}{\underset{\sim}{\sim}}$ | $\stackrel{\subset}{\infty}$ | $\stackrel{ᄃ}{\ominus}$ | $\frac{\square}{6}$ | $\stackrel{\smile}{\underset{\sim}{\sim}}$ | $\stackrel{\text { ᄃ }}{\infty}$ | $\frac{ᄃ}{\varrho}$ | $\stackrel{\square}{6}$ | $\stackrel{ᄃ}{\underset{~}{\sim}}$ | $\stackrel{\text { ¢ }}{\substack{\text { ¢ }}}$ |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $\left\lvert\, \begin{aligned} & \mathrm{IE} 2 \\ & =\mathrm{IE} 1 \\ & \hdashline \mathrm{IE} 1_{1-475} \end{aligned}\right.$ |
|  |  |  |  |  |  |  |  |  |  |  |  | , |  |  |  |  |  |  |  |  |  |  |  | - GAPDH |


| B |  | wt |  | mock |  |  |  | FXwt |  |  |  | FXrvIE1 |  |  |  | FXwt |  |  |  | FXIE1 $1_{1-475}$ |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\frac{\square}{0}$ | $\stackrel{\ulcorner }{\underset{\sim}{\sim}}$ | $\stackrel{\text { ᄃ }}{\infty}$ | $\begin{aligned} & \text { ᄃ } \\ & \varrho \end{aligned}$ | $\frac{ᄃ}{0}$ | $\stackrel{\ulcorner }{\underset{\sim}{\sim}}$ | $\stackrel{\subset}{\infty}$ | $\frac{ᄃ}{\mathscr{Q}}$ | $\stackrel{\text { c }}{6}$ | $\stackrel{ᄃ}{\underset{\sim}{\sim}}$ | $\stackrel{\perp}{\infty}$ | $\frac{ᄃ}{6}$ | $\frac{ᄃ}{0}$ | $\begin{aligned} & \text { ᄃ } \\ & \underset{\sim}{\prime} \end{aligned}$ | $\stackrel{\text { ᄃ }}{\infty}$ | ᄃ | $\frac{\square}{6}$ | $\stackrel{\text { c }}{\text { N }}$ | $\stackrel{\sim}{\infty}$ | $\frac{ᄃ}{6}$ | $\frac{\square}{0}$ | $\stackrel{\text { ᄃ }}{\text { N }}$ | $\stackrel{\text { ᄃ }}{\infty}$ | $\begin{gathered} \text { ᄃ } \\ 8 \end{gathered}$ |  |
|  |  |  | $=$ |  |  |  | , |  |  |  |  |  |  |  | -ma |  |  |  | $=$ | . |  |  |  |  |



Figure 9


## A

Human (Towne)
Chimpanzee
African green monkey
Rhesus macaque
Rhesus macaque (68-1)
Baboon
Human (Towne)
Chimpanzee
African green monkey
Rhesus macaque
Rhesus macaque (68-1)
Baboon

## Human (Towne)

Chimpanzee
African green monkey
Rhesus macaque
Rhesus macaque (68-1)
Baboon
Human (Towne)
Chimpanzee
African green monkey
Rhesus macaque
Rhesus macaque (68-1)
Baboon
Human (Towne)
Chimpanzee
African green monkey
Rhesus macaque
Rhesus macaque (68-1) Baboon

Human (Towne)
Chimpanzee
African green monkey
Rhesus macaque
Rhesus macaque (68-1)
Baboon
Human (Towne)
Chimpanzee
African green monkey
Rhesus macaque
Rhesus macaque (68-1)
Baboon
Human (Towne)
Chimpanzee
African green monkey
Rhesus macaque
Rhesus macaque (68-1)
Baboon
1 MESS-AKRKMDPD--------NPDEGPSSK-----VPRP---------ETPVTKATTFLQTMLRKEVN--SQLSL 50
1 MESSSGKRKMDSA--------NPDEGPSSK----IPRP-------ETPVSKACAFLTSMIQKEVN--SQLNL 51
1 MDPRQTKRKADDQPPQHTEGGDPGEGTSAG--PEPGPSPPKMSRYDDPGT-ERAVQFLEKLIEPETK--AVLNL 69
1 MDSR--KRKPEDE-THTGEAGDPEEGTSGG--PSTGPSPPKQAR--KDMALQHAVDLLEKMLADEEKKLTEFNL 67
1 MDSR--KRKPEDE-THTGEAVDPEEGTSGG--PSTGPSPPKQAR--KDMALQHAVDLLEKMLADEEKKLTEFNL 67
1 MDPRQLKRKADDE--QQSGQEDPGEGPSSGSPPAPGPSPPKMPRREDKNIHDEAVEFLEKLLAQETN--VVLSL 70
51 GDPLFPELA---EESLKTFERVTEDCNENPEKDVLAELVKQIKVRVDMVRHRIKEHMLKKYTQTEEKFTGAFNM 121
52 GDPLFPDVS---EDDLKSFEDVTKECDENPGKDILQELVKQIKVRVDIVRQKVKTHMLTKYMQMDEKFTAAFNN 122
70 GDPLFGYANVPEDEQFKTLEEIMNEDPQDPLR-KVQTLVYQIKLRVARTHTEIKNQHLQQFNDIRMGMEGKFKQ 142
68 GDPLFESA---NDDPIKTLEEIIQEG-DDVVG-AHQLVVTQIKLRVQRNRRLADEIIREQLTDIRKVFSDKFEK 136
68 GDPLFESA---NDDPIKTLEEIIQEG-DDVVG-AHQLVVTQIKLRVQRNRRLADEIIREQLTDIRKVESDKFEK 136
71 GDPLLHLSPVPEEVNMQSFEDILLENPGDVIR-QTQNVVWQIKLRLARNHTSHKNEGLFQLNQIRLEMGKEEVE 143


194 RAKKDELRRKMMYMCYRNIEFFTKNSAFPKTTNGCSQAMAALQNLPQCS-PDEIMAYAQKIFKILDEERDKVLT 266
195 QAKKEELNRKMTYIALKHVEFFTKNSAFPKTTNGTSAAIAALQSFHQCS-PEEVKCHAQRIMKTLDEERDKVLL 267
215 EMKQKDLQNRILYTHFKYSVMTVNSVTTPNISHGITQALIFLRGLPLHDDPETMINSGLNIIKLPDGEQTDLQI 288 209 KTKKGDIKDRVTYTCMKYLLMAMQGTGGPKAINNEEHVKLFFKQLSNYDDLTDANSAGLELIKKLDDEQKEVSF 282 209 KTKKDDIKDRVTYTCMKYLLMAMQGTGGPKAINNEEHAKLFFKQLSNYDDLTDANHDGLELIKKLDKEQKEVAF 282 218 EQKKNCIYESLHYATYAYAVQAVNSICLPKTVNSQEAAIMFLRGLPQHDGMEDVVRQGKQVMDMLDKEPNEIMN 291

267 HIDHIFMDILTTCVETMCNEYKVTSDACMMTMYGGISLLSEFCRVLSCYVLEETSVMLAKRPLITKPEVISVMK 340 268 HIDNIFMDILTTCVETMGNEYKVTSDASMMTMYGAISLLTEFCRVLSCYILEESSVMIARQPQITKEDLVSTMT 341 289 ENA-KFDALLLNIMNAFYKEGNSKNDEIMLSMYVPIQQTSIIMNSLSAFICDETAQIMYSKSHLSTEEIVKLMI 361 283 HVN-SFTHLVTTLGMALYKEGHQKNDEAMLGMHTPITMLSDQVRVIILYLIDEIVHAIHTNSNQSNDELIDGLK 355 283 HVN-NFTHLVTTLGMALYKEGHQKNDEAMLGMHTPITMLSDQVRVIILYLIDEIVHAIHTNSNQSNDELIDGLK 355 292 FSG-MEKHMLESIKLAFRKECSLTTDKYLMQMFAPVTQATAWVNTLSAFICHETADIVLRNPQITVEEIVKKMD 364

341 RRIEEICMKVFAQYILG-ADPLRVCSPSVDDLRAIAEESDEEEAIVAYTLATRGASSSDSLVSPPESPVP--AT 411 342 RRIQEICMRVFAQYLLG-CDPLRVCSPSVEDLRAIAEESDEDEAIAAHVRATAVSSP----ISPPDSPVPSESD 410 362 PKIQYLVREMYLKMCIDKTDKIKIWS--LAELREIVNDNEREASYAPVTGGVLPENVPSPDIPIESVMLYSDTE 433 356 PKVRIVINEFHATLMMG-TDRMRFYS--ISELRDIVNDKLNEDRFP-VVSGVLPENVPGTDIPLASVIIHSDTE 425 356 PKVRIVINE FHATLMMG-IDKMKFYS--LNELREIVNDKINEDRFP-VVSGVLPENVPGTDIPLASVIIHSDTE 425 365 FKIRAIVRDMFLKMVVDRTDKVKTQS--LEDFRKIIKEAEDEELLANIIGGDPFSAVSMRSESED----ESEEE 432

| 2 IPLS---------------------SVIV | QSDEEEEEGAQ | R----EDTVSVKSEPVS---- 455 |
| :---: | :---: | :---: |
| 411 IPLG-------------------TVTVAE | TSDEEADEGEESQAEVEEETQ | EEGEA-DDSVSVKSEPESEGEV 463 |
| 434 E------------------EESEAEEETE | TAEEEAEEQ-ETQIEQGTQAE | GQVEAETEGESEMVIPETEQGE 487 |
| 426 DEEEQDSDADEEEQESETDEEEQETETGDE | AETQAEETEEGTDETDIEGT | SETQIGSEAQPEAAESETQVEQ 499 |
| 426 D---------EEEQESEADDEEQETETGDE | GTETQAEETDEGTDETDIEGT | SETQIGSEAQPK-AESETQIEQ 489 |
| 433 E------------------EQAETDEEVE | TESEEEEQADTQAEEETQVE | QAAQTEEGQAEQAEEGQAEAG 487 |



## B

| GenBank | CMV | IE1 | CTD | NBM |
| :--- | :--- | :--- | :--- | :--- |
| AAR31448 | Human (Towne) | 100 | 100 | 100 |
| AAM00752 | Chimpanzee | 67.2 | 87.5 | 90.0 |
| AAB16882 | African green monkey | 26.3 | 62.5 | 80.0 |
| AAB00487 | Rhesus macaque | 25.1 | 62.5 | 80.0 |
| AAZ80666 | Rhesus macaque (68-1) | 24.2 | 56.3 | 70.0 |
| ACX71624 | Baboon | 23.9 | 56.3 | 90.0 |

## C



[^0]
[^0]:    $476477478479480 \underline{481} 482 \underline{483} 484 \underline{485} \mathbf{4 8 6} 487488489490491$

